Inhibitors of SOX18 protein activity for the treatment of angiogenesis- and / or lymphangiogenesis-related diseases - Patents.com

Specific compounds targeting SOX18 protein activity disrupt its DNA binding and protein interactions, effectively treating angiogenesis and lymphangiogenesis-related diseases by inhibiting SOX18 function.

JP7579057B2Active Publication Date: 2024-11-07THE UNIVERSITY OF QUEENSLAND
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2019534124
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-12-23
Filing Date
2017-12-21
Publication Date
2024-11-07
Estimated Expiration
2037-12-21

AI Technical Summary

Technical Problem

Current methods for inhibiting SOX18 protein activity lack selectivity and efficacy in targeting DNA binding and protein-protein interactions, limiting their applicability in treating angiogenesis and lymphangiogenesis-related diseases.

Method used

Development of specific compounds that directly bind to the SOX18 protein, disrupting its DNA binding and protein partner recruitment, thereby inhibiting its activity.

Benefits of technology

The compounds effectively inhibit SOX18 activity, providing therapeutic benefits in treating conditions such as cancer metastasis, vascular cancers, and other angiogenesis-related diseases by reducing pathological angiogenesis and lymphangiogenesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579057000031
    Figure 0007579057000031
  • Figure 0007579057000032
    Figure 0007579057000032
  • Figure 0007579057000033
    Figure 0007579057000033
Patent Text Reader

Abstract

Disclosed are compounds of the formulae provided herein that exhibit efficacy in inhibiting SOX18 protein activity, particularly related to the ability of SOX18 to bind to DNA and / or specific protein partners. Additionally provided herein are methods for treating angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of medicine. More particularly, the present invention relates to compounds for use in inhibiting SOX18 transcription factor activity. [Background technology]

[0002] Any reference in this specification to background art should not be construed as an admission that such art constitutes common general knowledge in Australia or anywhere else.

[0003] Direct regulation of transcription factors (TFs) by small molecules has long been sought. Early success was limited to nuclear receptors that contain ligand-binding domains that can be targeted by small molecules. These findings have been translated into therapeutic applications for hormone-dependent cancers (Perissi and Rosenfeld, 2005). The current challenge is to go beyond nuclear receptors to reach a broader range of transcription factors that lack binding pockets for small molecule drugs. This task is complicated by the lack of defined three-dimensional structures for many TFs, especially their protein-protein binding domains, the difficulty of recombinantly expressing TFs, and the lack of assay technologies to study their mechanism of action (Fontaine et al., 2015). Modulation of TF activity is generally achieved by altering their gene expression levels or concentrations in the nucleus, or by changing their binding ability to either DNA or partner proteins, the latter being a more promising strategy to achieve TF selectivity. Several publications on small molecules disrupting TF recruitment of partner proteins demonstrate the potential of this approach (Miyoshi et al., 2011; Vassilev et al., 2004; Filippakopoulos et al., 2010; Vogler et al., 2009; Liu et al., 2014).

[0004] Among TFs in the human genome, developmental TFs stand out as attractive molecular targets because their expression is often dysregulated under certain pathological conditions in adults, whereas they are silenced under physiological conditions (e.g., they are not required for phenotypic maintenance in adulthood) ( Boyadjiev and Jabs, 2000 ; Darnell, 2002 ; Lopez-Bigas et al., 2006 ; Vaquerizas et al., 2009 ). One class of developmental factors, SOX (SRY-related HMG-box) TFs, has recently emerged as key regulators of stem cell programming and molecular switches in cancer-related conditions ( Sarkar and Hochedlinger, 2013 ; Niwa et al., 2009 ). Previous attempts to target SOX proteins have mainly focused on SOX2 ( Narasimhan et al., 2011 ), a potential oncogene in various cancers ( Bass et al., 2009 ), and SOX18 ( Klaus et al., 2016 ), a key molecular switch for vascular development ( Cermenati et al., 2008 ; Francois et al., 2008 ; Pennisi et al., 2000 ). Dawson polyoxometalates have been shown to inhibit SOX2 DNA binding, but displayed only low selectivity towards various TF families and were never tested in any in vitro or in vivo functional assays (Narasimhan et al., 2014; Narasimhan et al., 2011). More recently, SOX DNA decoys have been used as selective inhibitors of SOX18 DNA binding and SOX18-dependent transcriptional promotion. These decoys show higher selectivity than non-SOX TFs, but are unable to diffuse through the cell membrane by themselves, limiting their scope of application ( Klaus et al., 2016 ). An underexplored aspect of the pharmacological modulation of SOX TFs relates to how these proteins recruit their partners and, consequently, regulate transcription through a range of diverse protein-protein interactions (PPIs). Presumably, synthetic libraries do not possess the structural diversity required to target PPIs (Hopkins and Groom, 2002; Feher and Schmidt, 2003).

[0005] The SOXF group of transcription factors (TFs) (SOX7, SOX17 and SOX18) are key regulators of endothelial cell differentiation during development (Francois et al., 2008; Corada et al., 2013; Hosking et al., 2009; Matsui et al., 2006; Cermenati et al., 2008; Herpers et al., 2008) and are therefore important for the formation of the vasculature. Mutations or deletions of the SoxF gene impair arteriovenous specification, vascular integrity and lymphangiogenesis, and inhibit tumor growth and metastasis in animal models of cancer (Duong et al., 2012; Yang et al., 2013; Zhang et al., 2009; Young et al., 2006). More recently, high levels of SOX18 have been associated with poor cancer prognosis in human patients ( Eom et al., 2012 ; Pula et al., 2013 ; Jethon et al., 2015 ). Thus, pharmacological inhibition of SOX18 protein function presents a potential avenue for the management of vascular responses in cancer, and a potential therapeutic target in vascular cancers. Summary of the Invention [Problem to be solved by the invention]

[0006] Thus, there remains a need for compounds that inhibit SOX18 protein activity, e.g., by binding directly to SOX18 protein or in proximity to its DNA-binding domain, e.g., by recruiting SOX18-protein partner and / or perturbing DNA binding of SOX18. [Means for solving the problem]

[0007] The present invention is based, at least in part, on the discovery that certain compounds of the formulae provided herein have efficacy in inhibiting SOX18 protein activity, particularly in relation to the ability of SOX18 to bind to DNA and / or certain protein partners. By extension, these compounds are further shown to be effective in treating angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancer.

[0008] In a first aspect of the present invention, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt, solvate or prodrug thereof: [ka] (In the formula, R1 is selected from the group consisting of OH and OR6; R6 is C1-C4 alkyl; R2 is selected from the group consisting of H, COOR7 and C(O)NR8R9; R7, R8 and R9 are independently selected from H and C1-C4 alkyl; R3 is LA, L is a linker selected from C2-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkoxyalkyl; and A is selected from optionally substituted phenyl and optionally substituted napthyl; R4 is H, OR 10 , halo, and C1-C4 alkyl; R 10 is selected from H and C1-C4 alkyl; and R5 is H, OR 11 , halo, and C1-C4 alkyl; R 11 is selected from H and C1-C4 alkyl; The compound is for use in inhibiting SOX18 activity.

[0009] In an embodiment, R1 is selected from the group consisting of OH and OMe.

[0010] Preferably, R2 is H, COOH, COOMe and [ka] is selected from the group consisting of:

[0011] Preferably, R2 is COOH and [ka] is selected from.

[0012] In an embodiment, R4 is selected from the group consisting of H, OH, OMe, Cl and Me.

[0013] Suitably, R5 is selected from the group consisting of H, OH and OMe.

[0014] In certain embodiments, R4 and R5 are H.

[0015] In embodiments, L is a linker selected from C2-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkoxyalkyl.

[0016] In any of the enumerated embodiments, R3: [ka] is selected from the group consisting of: wherein the dashed lines indicate bonds from adjacent atoms to the ring of formula I, and the structure shown includes its E / Z isomers.

[0017] In one embodiment, the compound of the first aspect is: [ka] JPEG0007579057000006.jpg231170JPEG0007579057000007.jpg61170.

[0018] More preferably, the compound of the first aspect is: [ka] JPEG0007579057000009.jpg214170JPEG0007579057000010.jpg61170.

[0019] Suitably, in the context of the compounds of this embodiment, the activity of SOX18 comprises contacting and / or binding to DNA sequences and / or proteins. Preferably, the protein is selected from the list consisting of SOX7, RBPJ, XRCC5, SOX18, ILF3, DDX17 and any combination thereof.

[0020] In a second aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the first aspect, or a pharma- ceutically acceptable salt, solvate or prodrug thereof, and a pharma- ceutically acceptable carrier, diluent and / or excipient.

[0021] In a third aspect of the present invention, there is provided a method of treating or preventing an angiogenesis- and / or lymphangiogenesis-associated disease, disorder or condition in a subject, the method comprising administering to the subject an effective amount of a compound of the first aspect, or a pharma- ceutical effective salt, solvate or prodrug thereof, or a pharmaceutical composition of the second aspect, thereby treating or preventing the angiogenesis- and / or lymphangiogenesis-associated disease, disorder or condition.

[0022] In a fourth aspect of the invention there is provided the use of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of angiogenesis- and / or lymphangiogenesis-associated diseases, disorders or conditions.

[0023] In reference to the third and fourth aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition preferably is or includes an ophthalmic disease, disorder or condition. Preferably, the ophthalmic disease, disorder or condition is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, ischemic retinopathy, retinopathy of prematurity, neovascular glaucoma, iritis rubeosis, corneal neovascularization, cyclitis, sickle cell retinopathy, pterygium, vascular response during corneal injury, and any combination thereof.

[0024] In an alternative embodiment of the third and fourth aspects of the invention, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or comprises cancer. Preferably, the cancer is selected from the group consisting of prostate cancer, lung cancer, breast cancer, bladder cancer, renal cancer, colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, melanoma, hepatocellular carcinoma, sarcoma, leukemia, acute T-cell lymphoma, angiogenic neoplasms, and any combination thereof. In certain embodiments, the compound of the first aspect or the pharmaceutical composition of the second aspect prevents and / or inhibits metastasis of said cancer.

[0025] In further embodiments of the two previous aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or includes a renal disease, disorder or condition. Preferably, the renal disease, disorder or condition is selected from the group consisting of chronic renal graft dysfunction, primary renal fibrotic disorder, proteinuria, diabetic nephropathy, renal inflammation and any combination thereof.

[0026] In another embodiment of the two previous aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or includes atherosclerosis.

[0027] In yet another embodiment of the two previous aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or includes Hypotrichosis-Lymphedema-Telangiectasia Syndrome.

[0028] In a fifth aspect of the invention, there is provided a method of inhibiting or preventing metastasis of cancer in a subject, the method comprising the step of administering to the subject an effective amount of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, or a pharmaceutical composition of the second aspect, thereby inhibiting or preventing metastasis of cancer.

[0029] Preferably, the cancer is selected from the group consisting of prostate cancer, lung cancer, breast cancer, bladder cancer, renal cancer, colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, melanoma, hepatocellular carcinoma, sarcoma, leukemia, lymphoma, vascular neoplasms (e.g., hemangioma, angiosarcoma, hemangioma), and any combination thereof.

[0030] In a sixth aspect of the present invention, there is provided a method for inhibiting, preventing or reducing SOX18 activity in a subject, the method comprising the step of administering to the subject an effective amount of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, or a pharmaceutical composition of the second aspect, thereby inhibiting, preventing or reducing SOX18 activity in the subject.

[0031] Suitably, SOX18 activity includes contacting and / or binding to DNA sequences and / or proteins. Preferably, the protein is selected from the list consisting of SOX7, RBPJ, XRCC5, SOX18, ILF3, DDX17 and any combination thereof.

[0032] In order that the invention may be readily understood and put to practical effect, preferred embodiments will now be described, by way of example only, with reference to the accompanying drawings in which: [Brief description of the drawings]

[0033] [Figure 1] A shows natural products, inhibitors of SOX18-DNA binding. A, Representative data set from high-throughput FP screening of 2688 marine extracts at 0.25 mg / mL. The screening was performed against full-length mouse SOX18 with a FAM-labeled SOX response element (mouse Prox1 intron 1). Competitive binding of ligands to SOX18 reduces the FP index (arrows pointing to red dot active extracts). B, Chemical structures of Sm1 and Sm2. C, FP concentration-response curves of Sm1 and Sm2 (full-length mouse SOX18, mean ± SDN=3). [Figure 2-1]A counter-screen using a structural analogue-focused library and in silico aggregation predictors, and a critical micelle concentration (CMC) assay. A, The first group is based on the ortho-hydroxybenzoic acid (salicylic acid) motif evident in compounds Sm1 and Sm2. The second group is based on a similar resorcinol backbone. The third group consists of approved NSAIDs containing similar salicylic or anthranilic acid backbone. B, Typical CMC data for two compounds Sm4 and Sm10 as well as a mild detergent Triton X100 control. C, SOX18-DNA binding inhibition by Sm4, meclofenamic acid, niflumic acid and flufenamic acid. [Figure 2-2] A counter-screen using a structural analogue-focused library and in silico aggregation predictors, and a critical micelle concentration (CMC) assay. A, The first group is based on the ortho-hydroxybenzoic acid (salicylic acid) motif evident in compounds Sm1 and Sm2. The second group is based on a similar resorcinol backbone. The third group consists of approved NSAIDs containing similar salicylic or anthranilic acid backbone. B, Typical CMC data for two compounds Sm4 and Sm10 as well as a mild detergent Triton X100 control. C, SOX18-DNA binding inhibition by Sm4, meclofenamic acid, niflumic acid and flufenamic acid. [Diagram 3]A and B are compounds that interact with SOX proteins but not DNA. Small molecule DNA binding was tested using biotinylated double-stranded DNA probes (approximately 40 base pairs long) with the SOX18 consensus element (A) or a scrambled sequence (B) flanking genomic DNA. Probes were immobilized on an SPR streptavidin chip. Positive controls DAPI, ethidium bromide, and actinomycin D bind DNA in a manner consistent with the literature. Small molecule inhibitors (Sm4, 5, and 14) do not bind to consensus or scrambled DNA. C is the thermal stability of SOX18 HMG fragment in the presence of either Prox1-DNA, Sm4, 5, or Sm14, measured by differential static light scattering of protein complexes heated from 25 to 80°C. Small molecule binding promotes protein stability (ΔTagg>3°C is considered significant stabilization). Boltzmann curve fit of normalized light scattering triplicate data (goodness of fit R>0.97).D, Sm4 inhibits DNA binding of SOX2, 6, 9, 11, 15 and 18-HMG fragments as measured using an FP-based DNA binding competition assay. [Figure 4]A is the effect of Sm4, niflumic acid, flufenamic acid and meclofenamic acid on SOX18 protein-protein interactions. The left panel in A is a heatmap of SOX18 pairwise protein-protein interactions tested by ALPHAScreen with XRCC6 (negative control) and two proteins known to interact with SOX18, RBPJ and MEF2C. The right panel in A is co-immunoprecipitation of protein complexes. SOX18-mCherry-cMyc was co-expressed with either GFP-RBPJ, GFP-MEF2C or GFP only (negative control) under cell-free conditions and immunoprecipitated with GFP Nanotrap beads. Bands are as follows: 1. RBPJ-GFP, 2. MEF2C-GFP, 3. SOX18-mCherry, 4. GFP. B shows the effects of Sm4, niflumic acid, flufenamic acid and meclofenamic acid on the interaction of SOX18 with MEF2C and RBPJ. [Figure 5-1]is the contribution of the Sm4 chemical motif to SOX18 DNA binding inhibition, SOX18-RBPJ binding inhibition, cytotoxicity and aggregation. The table in the top panel shows the Sm14-44 compounds and colour-codes the results obtained for the four activity markers, namely protein-DNA and protein-protein binding inhibition, cytotoxicity and aggregation risk. The second bottom bar graph details the SOX18-RBPJ protein-protein binding inhibition results at 50 μM and 5 μM, when available (N=4, mean ± SD). (DNA binding inhibition, cytotoxicity and cLogP raw data are summarised in Table 3). The bottom bar graph shows the SOX18-RBPJ protein-protein interaction (PPI) inhibition measured by the ALPHAScreen assay. Results are shown at 50 μM (PBS Ctrl, DMSO Ctrl and Sm4 in the left bars) and 5 μM (Sm4-Sm44 in the right bars). Note that results are shown when compounds are available (N=4, mean±SD). Comparison of disruption in PPIs of the Sm4 series tested at 5 μM, with SOX18 homodimer and SOX18 / RBPJ heterodimer formation as readouts in the ALPHAScreen assay. Some compounds preferentially disrupted SOX18 homodimer formation, while some others were more specific for SOX18 heterodimer formation, and some others are pan disruptors of both homo- and heterodimer complexes. [Figure 5-2]is the contribution of the Sm4 chemical motif to SOX18 DNA binding inhibition, SOX18-RBPJ binding inhibition, cytotoxicity and aggregation. The table in the top panel shows the Sm14-44 compounds and colour-codes the results obtained for the four activity markers, namely protein-DNA and protein-protein binding inhibition, cytotoxicity and aggregation risk. The second bottom bar graph details the SOX18-RBPJ protein-protein binding inhibition results at 50 μM and 5 μM, when available (N=4, mean ± SD). (DNA binding inhibition, cytotoxicity and cLogP raw data are summarised in Table 3). The bottom bar graph shows the SOX18-RBPJ protein-protein interaction (PPI) inhibition measured by the ALPHAScreen assay. Results are shown at 50 μM (PBS Ctrl, DMSO Ctrl and Sm4 in the left bars) and 5 μM (Sm4-Sm44 in the right bars). Note that results are shown when compounds are available (N=4, mean±SD). Comparison of disruption in PPIs of the Sm4 series tested at 5 μM, with SOX18 homodimer and SOX18 / RBPJ heterodimer formation as readouts in the ALPHAScreen assay. Some compounds preferentially disrupted SOX18 homodimer formation, while some others were more specific for SOX18 heterodimer formation, and some others are pan disruptors of both homo- and heterodimer complexes. [Figure 6]A is an in silico modeling of Sm4 at the interface between SOX18-HMG and RBPJ. Inhibition of SOX18-dependent transcriptional promotion in vitro. A and B are stable binding poses for Sm4 in the SOX18 / Prox1 DNA X-ray crystal structure, placing the inhibitor in the "open" pocket between the protein and DNA. C shows the docking of the SOX18 / DNA structure into the structure of the Notch transcription complex. D is a luciferase reporter assay (Hosking et al., 2004) in COS7 cells transiently transfected with a vector containing Sox18 and the Vcam1 promoter fused to the firefly luciferase gene. Cells were treated for 24 hours with small molecules at concentrations below CC10 (10% cytotoxicity) in culture medium containing up to 1% DMSO (v / v). Results are shown for Sm4 and niflumic acid. Meclofenamic acid and flufenamic acid were inactive at concentrations below CC10. [Figure 7] Figure 1 shows COX-1 / 2 enzyme inhibition. Figure 2 shows inhibition of COX-1 and COX-2 enzymes by SOX18 inhibitors, including meclofenamic acid as a positive control. Inhibition of COX enzymes is measured by the amount of PGH2 prostanoids generated from arachidonic acid conversion. [Figure 8-1] shows the NMR spectrum of Sm14-44. [Figure 8-2] shows the NMR spectrum of Sm14-44. [Figure 8-3] shows the NMR spectrum of Sm14-44. [Figure 8-4] shows the NMR spectrum of Sm14-44. [Figure 8-5] shows the NMR spectrum of Sm14-44. [Figure 8-6] shows the NMR spectrum of Sm14-44. [Figure 8-7] shows the NMR spectrum of Sm14-44. [Figure 8-8] shows the NMR spectrum of Sm14-44. [Figure 8-9]shows the NMR spectrum of Sm14-44. [Figure 8-10] shows the NMR spectrum of Sm14-44. [Figure 8-11] shows the NMR spectrum of Sm14-44. [Figure 8-12] shows the NMR spectrum of Sm14-44. [Figure 8-13] shows the NMR spectrum of Sm14-44. [Figure 8-14] shows the NMR spectrum of Sm14-44. [Figure 8-15] shows the NMR spectrum of Sm14-44. [Figure 9]Figure 1 shows the mapping of the global interactome of SOX18 and the disruption of the interaction by Sm4. (A) Schematic of the experimental strategy to deconvolute SOX18-dependent protein-protein interactions (PPIs) combining chromatin immunoprecipitation-mass spectrometry (ChIP-MS) and amplified luminescent proximity homogeneous assay (ALPHA-Screen) methods. (B) GO-term analysis of molecular functions for 289 proteins identified by SOX18-cMyc ChIP-MS in human umbilical vein endothelial cells (HUVECs). Non-specific interactors found in cells transfected with Myc-tag only were subtracted. For the continued direct interaction study, proteins with nucleic acid- or protein-binding capacity (purple) were considered to improve the chances of identifying direct interactors. (C) Left column: Heat map representation of SOX18 pairwise PPI tested by ALPHA-Screen for a selection of ChIP-MS SOX18-associated proteins, endothelial transcription factors and positive / negative control proteins. Right column: Heat map representation of Sm4 activity against SOX18-dependent protein-protein interactions tested at 100 μM. Interaction and disruption thresholds are indicated by black lines on the scale bar. Interaction and disruption levels above the threshold are defined by "+" and levels below the threshold are defined by "-". Tagged proteins were expressed in the Leishmania tarentolae cell-free protein expression system. (D) Representative ALPHA-Screen concentration-response curves for disruption of SOX18 PPI by Sm4 are shown. Data shown are mean ± sem. [Figure 10]Figure 2 shows the effect of QC and Sm4 on PPI of SOX18. (A) Mass spectrometry spectrum for a representative doubly charged DDX17 peptide (Muscat ion score 51.6) with sequence KAPILIATDVASRG identified from cMyc-SOX18 immunoprecipitation in HUVECs using anti-cMyc antibody. (B) Coverage of identified peptides of SOX18 and interacting proteins selected from ChIP-MS. (C) Amino acid sequence of DDX17 with identified ChIP-MS peptides shown in green. (D) Typical ALPHA-Screen curves for protein dilution optimization showing SOX9-SOX9 and SOX18-SOX18. The presence of a peak (hook effect) indicates the interaction and represents the ideal protein concentration for further binding studies. Proteins were expressed in Leishmania tarentolae cell-free protein expression system. (E) Molecular structure of Sm4, a SOX18 inhibitor. (F) ALPHA-Screen concentration-response curves for disruption of SOX18 PPI by Sm4. Data shown are means ± sem. [Figure 11] Differential disruption of PPI of SOXF by Sm4. Left panel shows a matrix of protein-protein interactions between SOXF, MEF2C and RBPJ and OCT4 measured by ALPHAScreen. Right panel shows the effect of 50uM Sm4 on PPI (blue=no PPI / disruption, green / yellow=low PPI / disruption, orange / red=strong PPI / full disruption, grey=PPI below threshold, Sm4 effect cannot be determined). [Figure 12]show that Sm4 selectively affects SOX18 transcriptional output in vitro. (A) Schematic of correlation analysis between genome-wide TF ChIP-seq data and Sm4-affected genes from transcriptomics data. Chromatin near the transcription start sites (TSS) of Sm4-affected genes (purple) was studied for transcription factor binding peaks (grey) and the "distance from TSS" to the nearest binding site for a given transcription factor was calculated. This distance from TSS was used as a surrogate for the potential for transcriptional regulation and thus formed the association between Sm4-affected genes and transcription factors (Cusanovich et al., PLoS Genetics, 2014; Verbist et al., Drug Discov Today, 2015). ChIP-seq peaks of SOX18 and SOX7, and all transcription factors available from the Encode consortium (GATA2, c-FOS, c-JUN, CTCF, EZH2, MAX and c-MYC) were included in the analysis performed in HUVEC. A random group of genes was analyzed as a control distribution, as would be found by chance. (B) Sm4-affected genes were grouped into downregulated (Sm4-down), unaffected (Sm4-unchanged) and upregulated (Sm4-up). The plot shows the cumulative distribution of the distance between the TSS of Sm4-affected genes (purple line, absolute fold change ≥ 2) and the nearest genomic location of the binding site for SOX18, as well as the control transcription factors SOX7 and GATA2. The median distance from the TSS of differentially expressed genes to the nearest binding event of a particular transcription factor was compared to the median distance expected by chance from a random set of genes (green line). Sm4 downregulated genes were significantly closer to the SOX18 peak (bold), but not to the SOX7 or GATA2 peaks. [Figure 13]Transcriptome-wide analysis of Sm4 selectivity in vitro. (A) Top motifs identified from SOX18 ChIP-seq peaks (MEME software) performed in HUVECs. (B) UCSC browser view of representative ChIP-seq peaks (arrowheads) for known SOX18 target genes VCAM and PROX1. (C) Conditions for transcriptome-wide analysis of Sm4. Differential expression (DE) was calculated between cells receiving vehicle DMSO (SOX18oe) and 25 μM Sm4 (Sm4) in SOX18-overexpressing HUVECs using DEseq2. (D) Principal component analysis of 4-plex RNA-seq samples. Combined replicate samples from the same condition (control, SOX18oe, Sm4) cluster. (E) Plot showing comparison of DESeq2 and edgeR methods, marking the significance of DE genes between SOX18oe and Sm4 conditions. Transcripts with DESeq2 Log2 fold change ≥1 or ≤-1 (dashed lines) were considered for further analysis. (F) Distances between genes affected by Sm4 (purple) and the nearest genomic location of a specific transcription factor binding site are plotted as cumulative distributions. The median distance from the TSS of differentially expressed genes to the nearest binding event of a transcription factor was expressed as a ratio to the median distance expected by chance (random genes, green). [Figure 14] shows that c-JUN motifs are enriched within SOX18 binding sites. (A) HOMER motif analysis on SOX18 ChIP-seq peaks revealed enrichment of the c-JUN motif 5'-TGAC / GTCA-3'. (B) ALPHA-Screen binding curves for SOX18-c-JUN and SOX18-SOX18 (positive control) are shown, indicating that c-JUN has the ability to directly interact with SOX18 in vitro. Proteins were expressed in the Leishmania tarentolae cell-free protein expression system. [Figure 15]Figure 1 shows that Sm4 does not interfere with SOX9 or SOX17 activity in vitro. (A) Cell-based reporter assay for SOX9 homodimer activity. COS-7 cells were transfected with Sox9 and Col2a1:luc reporter constructs. Sox9 overexpression resulted in a >8-fold induction of Col2a1 activation. No changes were observed at high concentrations of Sm4. (B) Cell-based reporter assay for SOX17 activity (Robinson et al., 2014). Bovine aortic endothelial cells (BAEC) were transfected with pTK-β-gal (pTK) or ECE1-TK-β-gal (ECE1) reporters and endogenous activity of SOX17 (ECE1 only) was measured. No changes were observed at any of the concentrations tested. Numbers on the x-axis are [Sm4] in μM. [Figure 16]shows that Sm4 blocks SoxF transcriptional activity in vivo. (A) Lateral bright field (top) and fluorescent (bottom) images of 60 hpf zebrafish larvae carrying the tg(-6.5kdrl:eGFP) SoxF reporter. Treatment began at late stage (20 hpf) with either DMSO (negative control) or 1 μM Sm4, or larvae were injected with morpholinos against both sox7 and sox18 (dMO sox7 / 18). Fluorescence intensity is shown as a heat map. Scale bar is 200 μm. (B) qRT-PCR analysis of gfp transcript levels in treated tg(-6.5kdrl:eGFP) larvae and sox7 / 18 morphants showing reduced activity for this transgene. (C) Lateral images of zebrafish larvae carrying a tg(Dll4in3:eGFP) SoxF / Notch reporter with multiple binding sites for Rbpj and SoxF transcription factors. Larvae were injected with morpholinos against rbpj and / or treated with 2 μM Sm4 from 13 hpf. (D) qRT-PCR analysis of gfp transcripts in tg(Dll4in3:eGFP) larvae showing repression of combined SoxF / Notch activity in Sm4-treated larvae. (E) Quantification of embryonic mortality in larvae treated with Sm4 or DMSO control from early stages (16 hpf) to 72 hpf. (F) Penetrance of vascular phenotype (arteriovenous shunt) in 48 hpf larvae treated with 1.5 μM Sm4 from 16 hpf. (G) Penetrance of vascular defects in 48 hpf larvae treated with 1.5 μM Sm4 from 16 hpf. (H) qRT-PCR analysis of endogenous endothelial transcript levels at 48 hpf in larvae treated with 1.5 μM Sm4 at 16 hpf versus DMSO control (dotted line). Data shown are mean ± sem. *p<0.05, **p<0.01, ***p<0.001. [Figure 17]shows that Sox9 activity is not perturbed by treatment in vivo. (A) Treatment timeline: Zebrafish larvae were treated for 4 consecutive days during chondrogenesis. The medium was refreshed daily throughout the experiment to maintain the levels of Sm4. (B) tg(col2a1:YFP) Sox9 reporter larvae (Mitchell et al., 2013) are shown showing cartilage. YFP levels were not affected in the presence of Sm4 and no changes in chondrogenesis were observed. mc: Meckel's cartilage, ch: ceratohyal, hs: hyosymplectic. (C) qRT-PCR of yfp transcript levels in DMSO control and Sm4 treated larvae at successive stages throughout chondrogenesis. [Figure 18]shows that Sm4 blocks SoxF activity in vivo. (A) Timeline of Sm4 treatment in zebrafish larvae. Treatment for SOXF reporter gene studies was initiated at 20 hpf, whereas for phenotypic studies, treatment was initiated earlier to affect during the right developmental window for arteriovenous specification. (B) Lateral view and transverse section of the trunk region of DMSO control and Sm4-treated tg(fli1:eGFP, -6.5kdrl:mCherry) larvae. Control DMSO larvae formed clearly separated dorsal aorta (DA) and posterior cardinal vein (PCV). In Sm4-treated larvae, the DA was constricted and / or fused to the PCV (arrowheads). Whole mount in situ hybridization for the arterial marker efnb2a showed reduced expression and impaired DA formation in Sm4-treated larvae at 48 hpf (arrows). Sections were stained with DAPI (in blue). Scale bars bright field: 0.5 mM, fluorescent and in situ 25 μm. (C) Concentration-dependent effects of Sm4, showing quantification of the predominant phenotype at 72 hpf: mild (tail curvature), moderate (dilated PCV) or severe (arteriovenous and / or circulation defect). The indicated time frame refers to the Sm4 treatment time and end point. (D) Quantification of the frequency of cardiac edema in larvae treated with Sm4 (1.5 μM). (E) qRT-PCR analysis of Sox18-dependent -6.5kdrl:mCherry and endogenous endothelial transcript levels in Sm4-treated larvae versus DMSO controls (dotted line) showing effects on arterial and venous markers at 24 hpf. All expression levels were normalized to expression of the endothelial marker cdh5. Data shown are mean ± sem. *p<0.05, **p<0.01, ***p<0.001. [Figure 19-1]shows that metastasis and tumor angiogenesis are suppressed by Sm4 treatment. (A) Timeline of mouse model for breast cancer metastasis. 4T1.2 tumors were inoculated on day 0 and excised on day 12. Sm4 (25 mg / kg / day), aspirin (25 mg / kg / day) or vehicle control (PBS) were orally administered daily from day 3 to day 12. Independent experiments were performed to evaluate survival and metastatic rates. (B) Plasma concentrations of Sm4 during the course of the treatment scheme (days 7 and 12) indicate good systemic delivery of the drug. (C) Expression of SOX18 within the tumor vasculature as shown by in situ hybridization. Scale bar 100 μm. (D) Mice survival was monitored (n=6-12 mice / group). Improved survival in Sm4-treated mice over both vehicle control and aspirin was analyzed by Log-rank test (p<0.001). (E) No significant differences in tumor size were found at any stage. (F) Metastatic tumor nodules on the surface of the lungs were quantified on day 28, before either vehicle control or Sm4-treated animals succumbed to the cancer burden. Data shown are the mean ± sem of 12–14 mice / group. (G) Vascular density was studied in 300 μm sections of whole tumors. Brightfield images show the overall morphology of the tumor (outlined by dashed lines) and the presence of red blood cells marking the main vessels and areas of hemorrhage (stars). Scale bar 1 mm. (H) Double immunofluorescence staining for the endothelial specific markers ERG and endomucin (EMCN) reveals vascular patterning and infiltration within the tumor and in the peritumoral area. Left: whole tumor section (scale bar 1 mm), center and right: enlargements of the encircled area (scale bar 200 μm). (I) Quantification of EMCN volume (vascular density) and ERG-positive nuclei (number of endothelial cells) of n=6 tumors / condition. Each data point represents the average of 3-4 representative fields (boxed areas in panel H) / tumor. Means ± sem for both conditions are shown. *p<0.05, **p<0.01. [Figure 21]FIG. 1 shows that vascular penetration into 4T1.2 tumors is impaired by Sm4. Brightfield images of serial vibratome sections (300 μm) from whole 4T1.2 mammary tumors of mice treated with PBS vehicle or Sm4. Major blood vessels and areas of hemorrhage are identified in red. [Figure 22] shows that Sm4-treated mice have reduced tumor vascular density. Immunofluorescence staining for ERG and endomucin (EMCN) on tumor sections. Two representative fields are shown for both vehicle PBS and Sm4. Detailed blow-ups show distinct nuclear staining for ERG and membranous endothelial staining for EMCN. Quantification of endothelial cell number and vessel volume was performed in Imaris on images with identical XYZ dimensions. Thresholds were selected to accurately capture total EMCN+ vasculature and total ERG+ nuclei (ERG number and EMCN volume shown in yellow). [Figure 23] Sm4 treatment disrupts tumor-induced lymphangiogenesis. Lymphatic vessel images of serial vibratome sections (200 μm) from whole 4T1.2 mammary tumors of mice treated with PBS vehicle or Sm4 (25 mg / kg / day). Immunofluorescence for lymphatic-specific markers PROX1 and podoplanin (PDPN) and vascular EC marker endomucin (EMCN) reveals vascular patterning and infiltration within the tumor and peritumoral regions. Whole tumor sections of control group (upper panel) and Sm4-treated group (lower panel). Quantification of PDPN+ lymphatic vessel area (density, upper graph) and PROX1+ nuclei (number of lymphatic endothelial cells, lower graph) for n≧6 tumors / condition. Scale bars left: 0.5 mm, right: 0.1 mm. Mean ± sem for both conditions is shown. **p<0.01, ***p<0.001. [Figure 24-1](A) shows the principle of single molecule tracking (SMT) experiments. SMT allows real-time imaging of chromatin binding dynamics of transcription factors such as SOX18 in living cells. SMT scans the genome to determine the search pattern of SOX18 protein while binding to specific response elements of its target genes. (B) Panel B shows the experimental workflow including two-dimensional tracking of molecular tracks and analysis using MATLAB. SOX18 molecules are either bound to DNA (immobile) or unbound and freely diffuse in the nucleus. Within the immobile fraction, it is possible to define two populations, either specifically bound or nonspecifically bound, based on their residence time on chromatin. (C) Top; Sm4 concentration-dependently increases the SOX18 specific binding fraction at the expense of the nonspecific binding fraction. Bottom; Sm4 increases the residence time of the specifically bound SOX18 fraction while decreasing the residence time of the nonspecifically bound fraction. (D): Top; Sm4 selectively binds to the SOX18 dominant-negative mutant Raop "Ragged Opossum" mutant, which in turn contributes to its partial rescue, since it reduces the Raop specific binding fraction at the benefit of the nonspecific binding fraction in a concentration-dependent manner. Bottom; Sm4 has the same effect on the residence time of the specifically and nonspecifically bound Raop fractions as it does on the SOX18 fraction, but the effect is more pronounced. [Figure 24-2](A) shows the principle of single molecule tracking (SMT) experiments. SMT allows real-time imaging of chromatin binding dynamics of transcription factors such as SOX18 in living cells. SMT scans the genome to determine the search pattern of SOX18 protein while binding to specific response elements of its target genes. (B) Panel B shows the experimental workflow including two-dimensional tracking of molecular tracks and analysis using MATLAB. SOX18 molecules are either bound to DNA (immobile) or unbound and freely diffuse in the nucleus. Within the immobile fraction, it is possible to define two populations, either specifically bound or nonspecifically bound, based on their residence time on chromatin. (C) Top; Sm4 concentration-dependently increases the SOX18 specific binding fraction at the expense of the nonspecific binding fraction. Bottom; Sm4 increases the residence time of the specifically bound SOX18 fraction while decreasing the residence time of the nonspecifically bound fraction. (D): Top; Sm4 selectively binds to the SOX18 dominant-negative mutant Raop "Ragged Opossum" mutant, which in turn contributes to its partial rescue, since it reduces the Raop specific binding fraction at the benefit of the nonspecific binding fraction in a concentration-dependent manner. Bottom; Sm4 has the same effect on the residence time of the specifically and nonspecifically bound Raop fractions as it does on the SOX18 fraction, but the effect is more pronounced. [Figure 24-3](A) shows the principle of single molecule tracking (SMT) experiments. SMT allows real-time imaging of chromatin binding dynamics of transcription factors such as SOX18 in living cells. SMT scans the genome to determine the search pattern of SOX18 protein while binding to specific response elements of its target genes. (B) Panel B shows the experimental workflow including two-dimensional tracking of molecular tracks and analysis using MATLAB. SOX18 molecules are either bound to DNA (immobile) or unbound and freely diffuse in the nucleus. Within the immobile fraction, it is possible to define two populations, either specifically bound or nonspecifically bound, based on their residence time on chromatin. (C) Top; Sm4 concentration-dependently increases the SOX18 specific binding fraction at the expense of the nonspecific binding fraction. Bottom; Sm4 increases the residence time of the specifically bound SOX18 fraction while decreasing the residence time of the nonspecifically bound fraction. (D): Top; Sm4 selectively binds to the SOX18 dominant-negative mutant Raop "Ragged Opossum" mutant, which in turn contributes to its partial rescue, since it reduces the Raop specific binding fraction at the benefit of the nonspecific binding fraction in a concentration-dependent manner. Bottom; Sm4 has the same effect on the residence time of the specifically and nonspecifically bound Raop fractions as it does on the SOX18 fraction, but the effect is more pronounced. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] definition As used in this patent specification, the terms "comprise," "comprising," "includes," "including," or similar terms are intended to imply a non-exclusive inclusion, and thus, a method or composition that includes a list of elements does not include only those elements, but may include other elements that are not listed.

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0036] The term "alkyl" as used herein refers to a straight or branched chain alkyl substituent containing, for example, from 1 to about 8 carbon atoms, preferably from 1 to about 7 carbon atoms, more preferably from 1 to about 6 carbon atoms, and even more preferably from 1 to about 4 carbon atoms. Examples of such substituents may be selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isoamyl, 2-methylbutyl, 3-methylbutyl, hexyl, heptyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-ethylbutyl, 3-ethylbutyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like. The carbon numbers referred to relate to the carbon backbone and carbon branches, but do not include carbon atoms belonging to any substituents, for example carbon atoms of alkyl or alkoxy substituents which branch off from the main carbon chain.

[0037] The term "alkenyl" refers to an optionally substituted unsaturated straight or branched hydrocarbon group having 2 to 8 carbon atoms, preferably 2 to 7 carbon atoms, more preferably 2 to 6 carbon atoms or 2 to 4 carbon atoms, and having at least one carbon-carbon double bond. Where appropriate, alkenyl groups can contain a specified number of carbon atoms, for example, C2-C6 alkenyl, which includes alkenyl groups having 2, 3, 4, 5 or 6 carbon atoms in a linear or branched arrangement. The carbon numbers referred to relate to the carbon backbone and carbon branches, but do not include carbon atoms belonging to any substituents. Examples of such substituents may be selected from the group consisting of ethenyl, propenyl, isopropenyl, butenyl, s- and t-butenyl, pentenyl, hexenyl, hepta-1,3-diene, hexa-1,3-diene, nona-1,3,5-triene, and the like.

[0038] The term "alkoxyalkyl," as used herein, means a straight-chain or branched-chain alkyl group linked through an oxygen atom (ie, alkyl-O-alkyl, also referred to as an "ether" group), where alkyl is defined above. In certain embodiments, alkoxyalkyl refers to an oxygen-linked group containing from 1 to 8 carbon atoms ("C1-8 alkoxyalkyl"). In further embodiments, alkoxyalkyl refers to an oxygen bridging group containing 2 to 8 carbon atoms ("C2-8 alkoxyalkyl"), 2 to 6 carbon atoms ("C2-6 alkoxyalkyl"), 2 to 4 carbon atoms ("C2-4 alkoxyalkyl") or 2 to 3 carbon atoms ("C2-3 alkoxyalkyl"). The number of carbon atoms listed refers to the entire alkoxyalkyl / ether chain.

[0039] As used herein, the term "optionally substituted" refers to substituents that may extend from related groups, such as phenyl or naphthyl groups, and includes halo, including F, Cl, and Br; C1-C4 alkyl; OR 12 (R 12 is C1-C4 alkyl); and NR 13 R 14 (R 13 and R 14 are independently selected from H and C1-C4 alkyl).

[0040] According to a first aspect of the present invention, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt, solvate or prodrug thereof: [ka] During the ceremony, R1 is selected from the group consisting of OH and OR6; R6 is C1-C4 alkyl; R2 is selected from the group consisting of H, COOR7 and C(O)NR8R9; R7, R8 and R9 are independently selected from H and C1-C4 alkyl; R3 is LA, L is a linker selected from C2-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkoxyalkyl; and A is selected from optionally substituted phenyl and optionally substituted napthyl; R4 is H, OR 10 , halo, and C1-C4 alkyl; R 10 is selected from H and C1-C4 alkyl; and R5 is H, OR 11 , halo, and C1-C4 alkyl; R 11 is selected from H and C1-C4 alkyl; The compounds are for use in inhibiting SOX18 activity.

[0041] In an embodiment, R1 is selected from the group consisting of OH and OMe.

[0042] Preferably, R2 is H, COOH, COOMe and [ka] is selected from the group consisting of:

[0043] Preferably, R2 is COOH and [ka] is selected from.

[0044] In an embodiment, R4 is selected from the group consisting of H, OH, OMe, Cl and Me.

[0045] Suitably, R5 is selected from the group consisting of H, OH and OMe.

[0046] In certain embodiments, R4 and R5 are H.

[0047] In embodiments, L is a linker selected from C2-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkoxyalkyl.

[0048] In any of the enumerated embodiments, R3 is: [ka] is selected from the group consisting of: wherein the dashed lines indicate bonds from adjacent atoms to the ring of formula I, and the structure shown includes its E / Z isomers.

[0049] In one embodiment, the compound of the first aspect is: [ka] JPEG0007579057000016.jpg233170JPEG0007579057000017.jpg61170.

[0050] In a preferred embodiment, the compound of this aspect is: [ka] JPEG0007579057000019.jpg213170JPEG0007579057000020.jpg62170.

[0051] Those of skill in the art will appreciate that SOX18 is a member of the SOX (SRY-related HMG-box) family of transcription factors. These transcription factors are typically involved in the regulation of embryonic development and cell fate decisions. In particular, the SOX18 protein may function as a transcriptional regulator after forming a protein complex with other proteins. SOX18 has been shown to play a role in hair, blood, and lymphatic vessel development. Other names for SASH1 include SRY-box 18, HLTS and HLTRS. Non-limiting examples of accession numbers referencing the nucleotide sequence of the SOX18 gene in humans, or its encoded protein, as are well understood in the art, include NG_008095.1, NM_018419.2, and NP_060889.1. "SOX18," as generally used herein, unless otherwise specified, may refer to a SOX18 nucleic acid or the encoded protein.

[0052] Suitably, the SOX18 activity that is modulated is that of lymphangiogenesis (i.e., the growth of new lymphatic vessels from existing lymphatic vessels), vasculogenesis (i.e., the de novo formation of embryonic circulatory systems) and / or angiogenesis (i.e., the growth of blood vessels from pre-existing vasculature).To this end, in an embodiment of the first aspect, one or more compounds of formula (I) may be useful for treating, reducing or preventing lymphangiogenesis, angiogenesis and / or vasculogenesis.

[0053] Thus, one or more compounds of formula (I) are preferably effective in preventing and / or reducing the severity of symptoms of angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions.

[0054] In one embodiment, SOX18 activity includes contacting and / or binding to DNA sequences and / or proteins. In this regard, the compounds of the first aspect may have an effect on one or more of the cell signaling pathways underlying angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions, including but not limited to inhibition of SOX18 DNA binding and / or protein-protein interactions.

[0055] In relation to DNA binding, SOX18 will be understood to be a transcription factor capable of binding to DNA via its HMG box, for example to the consensus sequence 5'-AACAAAG-3', and transactivating transcription via this binding. Furthermore, the SOX18 protein can function as a transcriptional regulator after forming a protein complex with one or more proteins.

[0056] As used herein, a "gene" is a nucleic acid that is a structural genetic unit of a genome, which may include, but is not limited to, one or more amino acid-encoding nucleotide sequences and one or more non-coding nucleotide sequences, including promoters and other 5' non-translated sequences, introns, polyadenylation sequences and other 3' non-translated sequences. In most cellular organisms, a gene is a nucleic acid that comprises double-stranded DNA.

[0057] As used herein, the term "nucleic acid" refers to single- or double-stranded DNA and RNA. DNA includes genomic DNA and cDNA. RNA includes mRNA, RNA, RNAi, siRNA, cRNA and autocatalytic RNA. The nucleic acid may also be a DNA-RNA hybrid. A nucleic acid comprises a nucleotide sequence that generally includes nucleotides that contain A, G, C, T or U bases. However, the nucleotide sequences may include other bases such as, but not limited to, inosine, methylycytosine, methylinosine, methyladenosine, and / or thiouridine.

[0058] "Protein" means an amino acid polymer. As one of skill in the art will appreciate, the term "protein" also includes within its scope phosphorylated forms of proteins (ie, phosphoproteins) and / or glycosylated forms of proteins (ie, glycoproteins). A "peptide" is a protein having 50 or fewer amino acids. A "polypeptide" is a protein having more than 50 amino acids.

[0059] Protein "variants" of SOX18, including naturally occurring (eg, allelic variants) and their orthologs, are also provided. Preferably, the protein variant shares at least 70% or 75%, preferably at least 80% or 85%, or more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence of SOX18 disclosed herein or known in the art.

[0060] As used herein, the term "protein-protein interaction" or "ΡPI" refers to a tight and stable binding between two or more proteins. This usually involves the formation of non-covalent chemical bonds, such as hydrogen bonds. PP1 can be bicomponent (two protein binding partners; a dimer) or ternary (three or more protein binding partners, eg, a trimer). The proteins (ie, binding partners) within a PPI can be the same protein (such as a homodimer or homotrimer) or different proteins (such as a heterodimer or heterotrimer). Preferably, the protein interaction is reversible, such that under suitable conditions, dissociation of SOX18 from the protein or protein subunit can occur. Preferably, such forces are weak, e.g., K in the μM range. d 's, and therefore the compounds of the present invention are capable of disrupting the interaction between SOX18 and proteins.

[0061] Preferably, the protein is selected from the list consisting of SOX7, RBPJ, XRCC5, SOX18, ILF3, DDX17 and any combination thereof.

[0062] In view of the above, one advantage of the compounds of the first aspect is that the clinical efficacy of the compounds for inhibiting DNA binding and / or specific protein-protein interactions by SOX18 can be somewhat tuned depending on the choice of groups around the core phenyl ring.

[0063] In some embodiments, compounds can be provided that have one or more chiral centers. Racemic mixtures of the compounds of the invention can be active, selective and bioavailable, although isolated isomers can also be of interest.

[0064] The compounds of the invention also include stereoisomers of the compounds described herein, and compositions containing more than one compound of the invention can, where appropriate, include such stereoisomers, e.g., E / Z isomers, either individually or mixed in any ratio. Stereoisomers may include, but are not limited to, enantiomers, diastereomers, racemic mixtures, and combinations thereof. Such stereoisomers can be prepared and separated using conventional techniques by reacting enantiomeric starting materials or by separating isomers of the compounds and prodrugs of the present invention. Isomers can include geometric isomers, examples of which include, but are not limited to, trans isomers or cis isomers (E / Z) at double bonds. Other isomers are contemplated among the compounds of the present invention. The isomers may be used either in pure form or in mixtures with other isomers of the compounds described herein.

[0065] Various methods are known in the art for the preparation of optically active forms and for the determination of activity. Such methods include standard tests described herein and other similar tests known in the art. Examples of methods that can be used to obtain optical isomers of the compounds according to the invention include the following: i) Physical separation of crystals, where macroscopic crystals of the individual enantiomers are manually separated. This technique can be used especially when crystals of separate enantiomers are present (i.e. the material is a conglomerate) and the crystals are visually distinct; ii) Simultaneous crystallization, where the individual enantiomers are crystallized separately from a solution of the racemate, which is only possible if the racemate is a conglomerate in the solid state; iii) enzymatic resolution, which is the partial or complete separation of a racemate due to differences in the rates of reaction of the enantiomers with an enzyme; iv) enzymatic asymmetric synthesis, which is a synthetic technique in which at least one step of the synthesis employs an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of a desired enantiomer; v) chemical asymmetric synthesis, in which the desired enantiomer is synthesized from an achiral precursor under conditions that result in asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries; vi) diastereomeric separation, which involves reacting a racemate with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers into diastereomers, and then separating the resulting diastereomers by virtue of their now more distinct structural differences, by chromatography or crystallization, with the chiral auxiliary subsequently removed to give the desired enantiomer; vii) Type 1 and type 2 asymmetric transformations, in which equilibration of diastereomers from a racemate causes the diastereomer from the desired enantiomer to predominate in solution, or preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium, thereby ultimately converting essentially all of the material to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then liberated from the diastereomer; viii) kinetic resolution, which involves partial or complete resolution of a racemate (or further resolution of a partially resolved compound) by differential reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions; ix) enantiospecific synthesis from non-racemic precursors, in which the desired enantiomer is obtained from non-chiral starting materials and the stereochemical integrity is not or only minimally compromised throughout the course of the synthesis; x) Chiral liquid chromatography, in which the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their different interactions with the stationary phase. The stationary phase may be made of chiral material or the mobile phase may contain additional chiral material to create different interactions; xi) chiral gas chromatography, in which the racemate is volatilized and the enantiomers are separated by their differential interaction with a column containing a fixed non-racemic chiral adsorbent phase in the gaseous mobile phase; xii) extraction with a chiral solvent, in which the enantiomers are separated by preferential dissolution of one enantiomer in a particular chiral solvent; and xiii) Transport through chiral membranes, where the racemate is placed in contact with a thin barrier. The barrier typically separates two miscible fluids, one of which contains the racemate, and a driving force such as a concentration difference or pressure difference causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral properties of the membrane, which allows only one enantiomer of the racemate to pass through.

[0066] The compounds of the first aspect may optionally be provided in enantiomerically or diastereomerically enriched compositions, such as mixtures of enantiomers or diastereomers, in which one enantiomer or diastereomer is present in excess, particularly to the extent of 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more (including 100%).

[0067] The compounds of the first aspect may be used per se or, where appropriate, in the form of a pharma- ceutically acceptable ester, amide, salt, solvate, prodrug or isomer. For example, the compounds may be provided as pharma- ceutically acceptable salts. When used, salts of drug compounds should be pharmacologically and pharma- ceutically acceptable, although pharma-ceutically unacceptable salts may be conveniently used in the preparation of the free active compound or its pharma-ceutically acceptable salt and are not excluded from the scope of the invention. Such pharmacologically and pharma- ceutically acceptable salts can be prepared by reaction of the drug with an organic or inorganic acid using standard methods well-known in the literature.

[0068] Examples of pharma- ceutically acceptable salts of compounds useful according to the present invention include acid addition salts. However, salts of acids that are non-pharmacologically acceptable may also be useful, for example, in the preparation and purification of the compound. Suitable acid addition salts according to the invention include organic and inorganic acids. Preferred salts include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, benzenesulfonic, and isethionic acid. Other useful acid addition salts include propionic, glycolic, oxalic, malic, malonic, benzoic, cinnamic, mandelic, salicylic acids, and the like. Specific examples of pharma- ceutically acceptable salts include sulfate, pyrosulfite, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, benzoic acid salts, and the like. Examples of suitable salts include, but are not limited to, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxyenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, gamma-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

[0069] Acid addition salts can be reconverted to the free base by treatment with a suitable base. Preparation of base salts of acid moieties which may be present on compounds or prodrugs useful according to the invention can be prepared in an analogous manner using a pharma- ceutically acceptable base, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, triethylamine, and the like.

[0070] Esters of compounds according to the invention can be prepared by functionalization of hydroxyl and / or carboxyl groups that may be present in the compounds. Amides and prodrugs can also be prepared using techniques known in the art. For example, amides can be prepared from esters, using suitable amine reactants, or they can be prepared from anhydrides or acid chlorides by reaction with ammonia or a lower alkyl amine. Additionally, esters and amides of the compounds of the present invention can be made by reaction with a carbonylating agent (e.g., ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride) and a suitable base (e.g., 4-dimethylaminopyridine, pyridine, triethylamine, potassium carbonate) in a suitable organic solvent (e.g., tetrahydrofuran, acetone, methanol, pyridine, N,N-dimethylformamide) at a temperature between 0°C and 60°C.

[0071] Examples of pharma- ceutically acceptable solvates include, but are not limited to, compounds according to the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.

[0072] According to a second aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the first aspect, or a pharma- ceutically acceptable salt, solvate or prodrug thereof, and a pharma- ceutically acceptable carrier, diluent and / or excipient.

[0073] Suitably, the pharma- ceutically acceptable carrier, diluent and / or excipient may be or include one or more of diluents, solvents, pH buffers, binders, fillers, emulsifiers, tablet disintegrants, polymers, lubricants, oils, fats, waxes, coatings, viscosity modifiers, glidants, and the like.

[0074] Salt forms of the compounds of the invention may be particularly useful due to their improved solubility.

[0075] Diluents may include one or more of microcrystalline cellulose, lactose, mannitol, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, and the like. The binders may include one or more of povidone, starch, stearic acid, gum, hydroxypropyl methylcellulose, and the like. Tablet disintegrants may include one or more of starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and the like. The solvent may include one or more of ethanol, methanol, isopropanol, chloroform, acetone, methyl ethyl ketone, methylene chloride, water, and the like. Lubricants may include one or more of magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oils, glyceryl behenate (behenate), and the like. Glidants may include one or more of the following: colloidal silicon dioxide, talc, or cornstarch. Buffers may include, but are not limited to, phosphate buffers, borate buffers and carbonate buffers. The filler may include one or more gels including, but not limited to, gelatin, starch, and synthetic polymer gels. The coating may include one or more of a film former, a solvent, a plasticizer, etc. Suitable film formers may be one or more of hydroxypropylmethylcellulose, methylhydroxyethylcellulose, ethylcellulose, hydroxypropylcellulose, povidone, sodium carboxymethylcellulose, polyethylene glycol, acrylates, etc. Suitable solvents may be one or more of water, ethanol, methanol, isopropanol, chloroform, acetone, methyl ethyl ketone, methylene chloride, and the like. Plasticizers may include one or more of propylene glycol, castor oil, glycerin, polyethylene glycol, polysorbates, and the like.

[0076] Handbook of Excipients 6 provides non-limiting examples of excipients that may be useful according to the present invention. th Edition, Eds. Rowe, Sheskey & Quinn (Pharmaceutical Press).

[0077] It will be appreciated that the choice of pharma- ceutically acceptable carrier, diluent and / or excipient will depend, at least in part, on the mode of administration of the formulation. By way of example only, the compositions may be in the form of a tablet, capsule, caplet, powder, injectable liquid, suppository, delayed release formulation, osmotic pump formulation, or any other form that is effective and safe for administration.

[0078] Suitably the pharmaceutical composition is for the treatment or prevention of a disease, disorder or condition in a mammal as described below. Preferably, the pharmaceutical composition is for the treatment or prevention of angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions in a mammal.

[0079] A third aspect of the invention resides in a method of treating or preventing angiogenesis- and / or lymphangiogenesis-associated diseases, disorders or conditions, comprising the step of administering an effective amount of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, or a pharmaceutical composition of the second aspect, thereby treating or preventing the angiogenesis- and / or lymphangiogenesis-associated disease, disorder or condition.

[0080] A fourth aspect of the invention provides the use of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment or prophylaxis of a disease, disorder or condition, such as angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition.

[0081] The terms "administering" or "administration" and the like, as generally used herein, describe the introduction of a compound or composition into a mammal, for example, by a particular route or vehicle. Routes of administration can include topical, parenteral and enteral, which includes, but is not limited to, oral, buccal, sublingual, nasal, anal, gastrointestinal, subcutaneous, intramuscular and intradermal routes of administration.

[0082] As used herein, "treating" (or "treat" or "treatment") refers to a therapeutic intervention that ameliorates signs or symptoms of angiogenesis- and / or lymphangiogenesis-related diseases, disorders, or conditions after their onset. The term "ameliorate" in connection with angiogenesis- and / or lymphangiogenesis-related diseases, disorders or conditions refers to any observable beneficial effect of treatment. The treatment need not be of absolute benefit to the subject. The beneficial effect can be determined using any standard method known to those of skill in the art.

[0083] As used herein, "preventing" (or "prevent" or "prevention") refers to a course of action (such as the administration of a therapeutically effective amount of one or more of the compounds described herein) initiated prior to the onset of a symptom, aspect or characteristic of an angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition to prevent or alleviate the symptom, aspect or characteristic. It is to be understood that such prevention need not be of absolute benefit to the subject. A "prophylactic" treatment is a treatment administered to a subject who does not show signs, or who shows only early signs, of an angiogenesis- and / or lymphangiogenesis-associated disease, disorder or condition, for the purpose of reducing the risk of developing a symptom, aspect or characteristic of an angiogenesis- and / or lymphangiogenesis-associated disease, disorder or condition.

[0084] As used herein, "effective amount" refers to administration of an amount of the relevant compound or composition sufficient to prevent the occurrence of, or cause the aggravation of, the symptoms of the condition being treated, or to treat and alleviate or at least reduce the severity of the symptoms. The effective amount will vary according to the patient's age, sex, weight, etc., as will be appreciated by those skilled in the art. The appropriate dosage or dosing regimen can be ascertained through routine clinical trials.

[0085] The term "subject" or "individual" or "patient" as used herein may refer to any subject for which treatment is desired, particularly vertebrate subjects, and more particularly mammalian subjects. Suitable vertebrates include, but are not limited to, primates, birds, farm animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes). A preferred subject is a human in need of treatment for an angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition described herein. However, it will be understood that the above terms do not imply that symptoms are necessarily present.

[0086] As used herein, the term "angiogenesis-related disease, disorder or condition" refers to any disease associated with abnormal blood vessel growth, including excessive blood vessel growth. It will be appreciated that the control of angiogenesis is altered in certain diseases, disorders or conditions. Many such diseases involve pathological angiogenesis (i.e., inappropriate, excessive or unwanted blood vessel formation), which supports the disease state and often contributes to the cell and tissue damage associated with such diseases. Angiogenesis-associated diseases, disorders or conditions (ie, those involving pathological angiogenesis) can be numerous and varied and can include, for example, various types of cancer, chronic inflammatory diseases, and angiogenic diseases. Examples of chronic inflammatory diseases, disorders or conditions include, but are not limited to, inflammatory disorders such as Crohn's disease and ulcerative colitis, rheumatoid arthritis, lupus, psoriasis, atherosclerosis and diabetes.

[0087] As used generally herein, the term "lymphangiogenesis-related disease, disorder or condition" refers to any disease associated with abnormal lymphatic vessel growth, including excessive lymphatic vessel growth. Lymphangiogenesis is ultimately controlled by a complex network of growth factors, cytokines and chemokines and can occur under a number of pathological conditions including, but not limited to, cancer growth and metastasis, inflammation and graft rejection (see, e.g., El-Chemaly, Ann NY Acad Sci (2008); Patel, Seminars Ophtalmol (2009); El-Chemaly, Lymphatic Res Biol (2009); Pepper, Clin Cancer Res (2001)). In relation to metastasis, cancer cells can spread via lymphatic vessels to lymph nodes and distant organs, which is often the first step in the spread of cancer cells beyond the primary cancer.

[0088] In one embodiment of the third and fourth aspect, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or comprises an ophthalmic disease, disorder or condition, in particular one involving angiogenesis. To this end, angiogenesis and / or lymphangiogenesis may play a central role in the development of ophthalmic diseases, disorders or conditions, such as age-related macular degeneration, diabetic retinopathy, ischemic retinopathy, retinopathy of prematurity, neovascular glaucoma, iritis rubeosis, corneal neovascularization, cyclitis, sickle cell retinopathy, vascular response during corneal injury and pterygium. As these ophthalmic diseases, disorders or conditions progress, not only can the blood vessels of the eye proliferate excessively, but the new blood vessels can also be weak, leaky and prone to bleeding. Therefore, the new abnormal blood vessels can bleed and subsequently cause the subject to lose vision.

[0089] In one embodiment of the third and fourth aspects, the angiogenesis and / or lymphangiogenesis-related disease, disorder or condition is or comprises cancer.For this purpose, the formation and metastasis of cancer typically involves pathological angiogenesis.Like healthy tissue, cancer requires new blood vessel formation to provide nutrients and oxygen and remove cellular waste products.Therefore, pathological angiogenesis is important for the growth and spread of cancer.

[0090] As generally used herein, the terms "cancer," "tumor," "malignancy," and "malignant tumor" refer to a disease or condition, or a cell or tissue associated with a disease or condition, characterized by unregulated or abnormal cell proliferation, differentiation, and / or metastasis, often accompanied by an unregulated or abnormal molecular phenotype including one or more genetic mutations or other genetic alterations associated with oncogenesis, expression of tumor markers, loss of tumor suppressor expression or activity, and / or unregulated or abnormal cell surface marker expression.

[0091] Cancer can include any aggressive or potentially aggressive cancer, tumor or other malignancy, such as those listed in the NCI Cancer Index at http: / / www.cancer.gov / cancertopics / alphalist, including all major forms of cancer, such as, but not limited to, sarcoma, carcinoma, lymphoma, leukemia, and blastoma. these are, Breast cancer, lung cancer including lung adenocarcinoma, Cancers of the reproductive system, including ovarian, cervical, uterine and prostate cancer; Brain and nervous system cancers, head and neck cancers, gastrointestinal cancer, including colon cancer, colorectal cancer and gastric cancer; liver cancer, kidney cancer, skin cancer such as melanoma and skin carcinoma; Blood cell cancers, including lymphoid and myelomonocytic cancers; cancers of the endocrine system, such as pancreatic cancer and pituitary cancer; musculoskeletal cancers, including bone and soft tissue cancers; These may include, but are not limited to, vascular cancers or neoplasms such as hemangiomas, hemangiomas, and hemangiosarcomas.

[0092] In certain embodiments, the cancer is selected from the group consisting of prostate cancer, lung cancer, breast cancer, bladder cancer, renal cancer, colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, melanoma, hepatocellular carcinoma, hepatocellular carcinoma, sarcoma, leukemia, lymphoma, vascular neoplasms such as hemangioma, angioma, and angiosarcoma, and any combination thereof.

[0093] In one particular embodiment, the compound of the first aspect or the pharmaceutical composition of the second aspect prevents and / or inhibits metastasis of said cancer.

[0094] As used herein, "metastasis" or "metastatic" refers to the dislocation or migration of malignant cancer cells or neoplasms, typically from a primary focus of a tumor, cancer or neoplasm, to a distant site within the body, via the circulatory or lymphatic system or via a natural body cavity, and the subsequent development of one or more secondary tumors or colonies thereof at one or more new locations. "Metastasis" refers to secondary tumors or colonies formed as a result of metastasis, and includes micrometastases, as well as local and distant metastases.

[0095] It will be appreciated that pathological angiogenesis and lymphangiogenesis may play an important role in cancer metastasis. To this end, the formation of blood vessels in a primary cancer not only allows cancer cells to enter the bloodstream and circulate throughout the body, but also supports the formation and growth of metastatic cancers seeded by cancer cells that have metastasized from the primary site.

[0096] In further embodiments of the two previous aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or includes a renal disease, disorder or condition. Preferably, the renal disease, disorder or condition is selected from the group consisting of chronic renal graft dysfunction, primary renal fibrotic disease, proteinuria, diabetic nephropathy, renal inflammation, and any combination thereof.

[0097] In one particular embodiment of the third and fourth aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or includes atherosclerosis. To this end, those skilled in the art will recognize that the pathological changes in atherosclerosis can be attributed, at least in part, to chronic inflammation and angiogenesis. Furthermore, a link between NF-kB-dependent atherogenic inflammatory responses and SOX18 regulation has been shown, suggesting that SOX18 may play a role in the development of atherosclerosis (Garcia-Ramirez et al., 2005). Sox18 has also been shown to be overexpressed in atherosclerotic lesions and may therefore be a key component in disease pathogenesis (Brown et al., 2014).

[0098] In one embodiment of the third and fourth aspects, the angiogenesis- and / or lymphangiogenesis-related disease, disorder or condition is or includes Hypotrichosis-Lymphedema-Telangiectasia Syndrome. In this regard, it will be noted that Hypotrichosis-Lymphedema-Telangiectasia Syndrome is associated with mutations in the SOX18 gene.

[0099] In a fifth aspect, the present invention provides a method of preventing or inhibiting metastasis of cancer in a subject, the method comprising the step of administering to the subject an effective amount of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, or a pharmaceutical composition of the second aspect, thereby inhibiting or preventing metastasis of cancer.

[0100] Suitably the cancer is as previously described herein.

[0101] A sixth aspect of the present invention resides in a method of inhibiting, preventing or reducing SOX18 activity in a subject, the method comprising the step of administering an effective amount of a compound of the first aspect, or a pharma- ceutically effective salt, solvate or prodrug thereof, or a pharmaceutical composition of the second aspect, thereby inhibiting, preventing or reducing SOX18 activity in the subject.

[0102] Suitably, SOX18 activity comprises contacting and / or binding to a DNA sequence and / or a protein. Preferably, the protein is selected from the list consisting of SOX7, RBPJ, XRCC5, SOX18, ILF3, DDX17 and any combination thereof.

[0103] The various features and embodiments of the invention referred to in individual sections above apply mutatis mutandis to other sections as appropriate. Consequently, features detailed in one section may be combined with features detailed in other sections as appropriate.

[0104] The experimental section which follows describes in more detail the properties of certain compounds of the invention, and their efficacy. The present invention illustrates certain specific embodiments of the compounds of the present invention and their effectiveness without limiting the invention in any way. EXAMPLES

[0105] Example 1 material and method Preparation of compounds Marine Extract Library A library of n-butanol fractions generated from marine product libraries collected across Australia and Antarctica was used for screening. The active fractions were fractionated to give pure compounds which were re-assayed in the same manner as the original fractions.

[0106] A library of 2688 samples of marine invertebrates and algae collected across South Australia and the Antarctic was processed to generate a library of extracts suitable for high throughput bioassays. The EtOH extract was decanted, concentrated, and partitioned into n-BuOH and H2O phases before being transferred to a deep 96-well plate to provide a >10-fold concentration of small molecules while removing salts. The n-BuOH fraction (25 mg / mL w / v of dry residue) was used for screening after 10- and 100-fold dilutions (2.5 and 0.25 mg / mL). The active fractions were triturated in hexane, CH2Cl2 and MeOH and fractionated into pure compounds by HPLC. All compounds were assayed in the same manner as fractions.

[0107] Sm1 (6-undecylsalicylic acid) and Sm2 (6-tridecylsalicylic acid) were purified from an aqueous EtOH extract of the original brown algae sample, Caulocystis cephalornithos (CMB-01671). An aqueous EtOH extract of a sample of the brown alga Caulocystis cephalornithos (CMB-01671) was concentrated under vacuum (4.8 g) and partitioned into n-BuOH (0.80 g) and HO (4.0 g) soluble material. An aliquot (40 mg) of the n-BuOH soluble partition was subjected to HPLC fractionation (Agilent Zorbax SB C18 5 μM, 250 × 9.4 mm column, 4 mL / min gradient elution from 60% MeOH / HO to 100% MeOH in 10 min, then 100% MeOH in 10 min, isocratic composition with 0.01% TFA modifier) ​​to give 6-undecylsalicylic acid (Sm1, 5.9 mg, RT 12.8 min) and 6-tridecylsalicylic acid (Sm2, 11 mg, RT 13.7 min).

[0108] Sm4~Sm14 - Focused Library Synthetic analogs were purchased from EndoTherm GmbH (Germany) and Princeton BioMolecular Research (USA) and analyzed for purity by HP-LC / MS.

[0109] Sm15~Sm44 SAR Library A SAR library was designed to explore the role of the lipophilic tail and possible substituents on the salicylic acid backbone. The six-step synthesis outlined below begins with a substituted benzoic acid and uses a Wittig olefination reaction to introduce the lipophilic tail. Partially protected intermediates were also included in the SAR library. All compounds were purified by HPLC (purity >90%, UV / ELSD / MS). [ka]

[0110] General Materials and Methods Reagents and anhydrous solvents (THF, dichloromethane and acetonitrile) were used as received. The progress of the reaction was monitored by TLC using Merck silica gel 60 F-254 with UV detection. Silica gel 60 (Merck 40-63 μm) was used for column chromatography. The following staining solutions were used with fluorescent TLC plates in addition to UV light: phosphomolybdic acid, anisaldehyde / EtOH. Reactions requiring anhydrous conditions were carried out under nitrogen. NMR data were collected and calibrated at 298 K in d4-MeOH or CDCl3 on a Varian Unity 400 MHz or Bruker Avance 600 MHz spectrometer. HPLC and assigned mass spectra were obtained on an Agilent Technologies 1200 Series instrument equipped with a G1316A UV-Vis detector, a 1200 Series ELSD and a 6110 quadrupole ESI-MS. High resolution mass spectrometry (HRMS) was performed on a Bruker MicroTOF mass spectrometer.

[0111] General procedure for the preparation of N,N-diethylbenzamides (4a-d) 1 Substituted N,N-diethylbenzamides were prepared from each of the substituted benzoic acids. The acid (5 g, 32.9 mmol) was refluxed with excess thionyl chloride (50 mL) until the evolution of hydrogen chloride ceased. Excess thionyl chloride was removed under reduced pressure and codistilled with toluene (3×15 mL). The acid chloride was dissolved in dry CH2Cl2 (100 mL) and diethylamine (13.6 mL, 131.5 mmol) was added dropwise at 0° C. and stirred at room temperature overnight. The reaction mixture was diluted with CH2Cl2 (100 mL), washed with water (50 mL), brine solution and dried over anhydrous MgSO4. The organic layer was removed on a rotary evaporator to give the crude compound. The crude compound was purified by flash column chromatography to give pure diethylbenzamide.

[0112] General procedure for directed orthometalation reactions (5a-d) 2 To a solution of TMEDA (0.55 mL, 3.7 mmol) in dry THF (10 mL) was added s-BuLi (2.6 mL, 3.7 mmol, 1.5 M in cyclohexane) at -78°C and, after stirring for 15 min, 1-methoxy-N,N-diethylbenzamide (0.35 g, 1.7 mmol) in THF (5 mL) was added. After stirring at the same temperature for 2 hours, anhydrous DMF (0.52 mL, 6.8 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature and stirred for 30 min. The reaction was quenched by the addition of 6N aqueous HCl (10 mL) and extracted with ethyl acetate (3×15 mL). The combined organic layers were washed with brine (10 mL) and dried over MgSO4. After removal of the solvent under vacuum, the residue was purified by flash column chromatography (n-hexane / ethyl acetate, 1 / 2) to give the product.

[0113] General procedure 3 for the cleavage of N,N-diethylbenzamides (10a-d) N,N-Diethylbenzamide (1.3 mmol) was dissolved in glacial acetic acid (3 mL), 10% aqueous HCl (3 mL) was added, and the mixture was refluxed for 12 h. After cooling to room temperature, the acetic acid was removed under reduced pressure, diluted with water and extracted with EtOAc (30 mL). The organic layer was washed with brine, separated and dried over anhydrous MgSO4. The solvent was removed under reduced pressure to give the product.

[0114] General Procedure for Wittig Olefination Reaction (12a-d)4 To a suspension of Wittig salt (1.0 mmol) in THF (10 mL), t-BuOK (2.0 mmol) or NaH (2.0 mmol) was added at 0° C. and stirred for 30 min. The aldehyde (0.8 mmol) dissolved in THF was added slowly and stirred at room temperature overnight (reactions were carried out at 50° C. using NaH, entries 2, 4, 5, 6). The reaction was quenched with water and extracted into EtOAc (30 mL). The organic layer was washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo to give the crude compound. The crude compound was purified by flash column chromatography to give the pure product.

[0115] General procedure for demethylation: Method A (BBr 3 Use 5 A solution of the compound (74 mg, 0.192 mmol) in methylene chloride (70 mL) was treated with BBr3 (1.0 M in methylene chloride, 0.576 mL, 0.576 mmol) at -78 °C. The mixture was stirred at -78°C for 2 h and then quenched with saturated aqueous NH4Cl (10 mL). The mixture was allowed to reach room temperature and was diluted with methylene chloride (30 mL). The organic layer was washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo.

[0116] General procedure for demethylation: Method B (using HBr)6 The compound (100 mg, 0.192 mmol) in 48% HBr aqueous solution (3.0 mL) was heated to reflux for 3 hours. After completion of the reaction, it was allowed to warm to room temperature and evaporated under reduced pressure to give a crude residue. The crude compound was extracted with EtOAc (30 mL) and washed with water (20 mL). The organic layer was separated, dried (MgSO4) and concentrated to give the product.

[0117] General methods for the reduction of olefins (14a-d). To a 1:1 (EtOAc:MeOH) solution of the olefin was added 10% Pd / C (10 mol %) and stirred under a hydrogen atmosphere at room temperature for 2 h. After completion of the reaction, it was filtered through a bed of celite. The filtrate was removed under reduced pressure to give the product.

[0118] Protein preparation Mouse SOX HMG fragment The HMG domains of mouse SOX2 (group B), SOX11 (group C), SOX6 (group D), SOX9 (group E), SOX18 (group F) and SOX15 (group G) were BP cloned from cDNA templates (IMAGE cDNA Clone IDs: Sox18:3967084; Sox9:5354229; Sox4:6822618) into pDONRTM221 pENTRY vector, sequenced and incorporated into pETG20A or pHisMBP expression plasmids using Gateway® LR Technology (Ng et al., 2012). The constructs were transformed into Escherichia coli BL21(DE3) cells (Luria-Bertani, 100 μg / ml ampicillin).

[0119] Full-length mouse SOX18 N-terminally tagged mouse HIS-GST-SOX18 was recombinantly expressed in Sf9 cells, purified on GST resin (GE Healthcare Life Sciences, Sweden) and eluted in Tris buffer (50 mM Tris, 500 mM NaCl, 10 mM reduced glutathione, pH 8.0). A cDNA clone of mouse Sox18 was PCR amplified and cloned into the pOPIN-GST vector to generate N-terminally tagged HIS-GST-SOX18. Sequence-verified constructs were co-transfected with flashBACULTRA (Oxford Expression Technologies, Oxford, United Kingdom) baculovirus DNA into Spodoptera frugiperda Sf9 cells to obtain recombinantly expressed HIS-GST-SOX18. High Five cells (BTI-TN-5B1-4) in Sf-900™ II serum-free medium were cultured at 1.5 × 10 6 Cells were infected at a multiplicity of infection (MOI) of 5 PFU / cell at a cell density of 1000 cells / mL and incubated at 21° C. for 144 hours before harvesting. Cell pellets from 100 mL of expression culture were resuspended in 30 mL of phosphate lysis buffer (50 mM sodium phosphate, 500 mM sodium chloride, 1% Triton X-100, 2 mM magnesium chloride, 1 tablet of cOmplete Protease Inhibitor Cocktail, pH 7.5) and sonicated for 20 seconds on ice. The cell lysate was centrifuged at 17,000 xg at 4°C for 40 minutes. The supernatant was incubated with Benzonase Nuclease (Merck Millipore) for DNA degradation at room temperature for 1 h, then mixed with 500 μL of GST resin (GE Healthcare Life Sciences, Sweden) and incubated on a rotating wheel at room temperature for 1 h. The samples were centrifuged at 500×g for 1 min to remove unbound proteins in the supernatant. The resin was further washed with 50 resin volumes (RV) of wash buffer (50 mM sodium phosphate, 500 mM NaCl, pH 7.5) and unbound protein was removed by centrifugation as above. Bound proteins were eluted from the resin with 3x1 RV elution buffer (50 mM Tris, 500 mM NaCl, 10 mM reduced glutathione, pH 8.0) and the supernatant was collected by centrifugation as above.

[0120] DNA binding competition assay using fluorescence polarization (FP) DNA binding competition assays were performed in black 384-well plates with mouse full-length SOX18, or the SOX-HMG fragment. All experiments were performed using fluorescently labeled Prox1-DNA elements. Controls consisted of free labeled DNA (low FP milli-polarization index, mP), labeled DNA in the presence of protein (negative control, high mP), and labeled DNA and protein in the presence of excess competing unlabeled DNA (positive control, low mP).

[0121] DNA binding competition assays were performed in 25 uL in black 384-well plates using 30 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) (pH 7.5, with 100 mM KCl, 40 mM NaCl, 10 mM NH4OAc, 10 mM guanidinium, 2 mM MgCl2, 0.5 mM EDTA, 0.01% NP-40) for mouse full-length SOX18 and Tris-NaCl (10 mM Tris pH 8.0 and 100 mM NaCl) for SOX-HMG fragments. All experiments were performed using a 40 bp double-stranded Prox1-DNA element with a 5′ fluorescein amidite (FAM) label (Sigma Proligo or InVitrogen). Optimal binding levels were obtained with 200 nM mouse full-length SOX18 and 60 nM SOX-HMG fragment in the presence of 5 nM labeled DNA. Controls consisted of free labeled DNA (low FP milli-polarization index, mP), labeled DNA in the presence of protein (negative control, high mP), and labeled DNA and protein in the presence of a 400-fold competing excess of unlabeled DNA (positive control, low mP). Depending on the compound, final DMSO concentrations ranged from 2 to 3.33% v / v. After mixing the proteins, DNA probes and compounds, the plates were sealed and quickly mixed in the dark at room temperature for 5 min, at 37°C for 10 min and at room temperature for 30 min before the fluorescence polarization was read on a Tecan M1000Pro (λexc=485 nm, λem=525 nm). All experiments were performed in triplicate.

[0122] Cell-based functional assays Monkey kidney fibroblast-like cells (COS-7) were cultured in DMEM (Life technologies, 11995) with FBS, sodium pyruvate, L-glutamine, penicillin, streptomycin, non-essential amino acids and HEPES at 37°C and 5% CO2. Cells were grown in 96-well plates to 80% confluency and transfected with mouse plasmids pGL2 Vcam 1 promoter construct (VC1889) and pSG5 Sox18 ( Hosking et al., 2004 ; Duong et al., 2014 ) using X-tremeGENE 9 DNA transfection reagent (Roche, 06365787001). After 4-6 hours of transfection, cells were incubated with compounds in 0.5% FBS medium for an additional 24 hours before lysis and luciferase assay (Perkin Elmer, 6016711).

[0123] Cell-free expression and ALPHA screening Plasmid preparation and cell-free expression All proteins were genetically encoded with enhanced GFP (GFP), mCherry and cMyc (myc) tags and cloned into cell-free expression vectors ( Gagoski et al., 2015 ; Sierecki et al., 2013 ). Translation competent Leishmania tarentolae extract (LTE) was prepared to co-express protein pairs as previously described ( Kovtun et al., 2011 ; Mureev et al., 2009 ).

[0124] Proteins were genetically encoded with enhanced GFP (GFP), mCherry and cMyc (myc) tags and cloned into cell free expression Gateway destination vectors: N-terminal GFP tagged (pCellFree_G03), N-terminal Cherry-cMyc (pCellFree_G07) and C-terminally Cherry-cMyc tagged (pCellFree_G08) ( Gagoski et al., 2015 ). Human RBPJ (BC020780) and MEF2C (BC026341) open reading frames (ORFs) were sourced from the human ORFeome collection, versions 1.1 and 5.1, and the human Orfeome collaboration OCAA collection (Open Biosystems), as previously described (Sierecki et al., 2013), and cloned at the ARVEC facility, UQ Diamantina Institute. The entry clone pDONOR223 or pENTR201 vector was exchanged for the ccdB gene in the expression plasmid by LR recombination (Life Technologies, Australia). The full-length human SOX18 gene was synthesized and transfer into the vector was achieved using Gateway PCR cloning. Translation-competent Leishmania tarentolae extracts (LTE) were prepared as previously described ( Kovtun et al., 2011 ; Mureev et al., 2009 ). The protein pairs were co-expressed by adding 30 nM GFP template plasmid and 60 nM Cherry template plasmid to the LTE and incubating at 27° C. for 3 hours.

[0125] ALPHAScreen was performed as previously described ( Sierecki et al., 2014 , Sierecki et al., 2013 ). Protein-protein interactions (IC 50 Assays for disruption of the interaction were performed by expressing protein pairs in LTE and incubating for 1 h with a dilution range of test compounds (0.3-300 μM) in buffer B or DMSO (0.7% DMSO final). The percentage of interaction was calculated from three independent experiments as follows: (I_cpd / I_DMSO) × 100.

[0126] ALPHASreen was performed as previously described ( Sierecki et al., 2014 , Sierecki et al., 2013 ) using a cMyc detection kit and Proxiplate-384 Plus plates (PerkinElmer). LTE lysates co-expressing the protein of interest were diluted in Buffer A (25 mM HEPES, 50 mM NaCl). For the assay, 12.5 μL (0.4 μg) of anti-cMyc-coated acceptor beads in buffer B (25 mM HEPES, 50 mM NaCl, 0.001% NP40, 0.001% casein) were aliquoted into each well. Then, 2 μL of diluted samples at different concentrations and 2 μL of biotin-labeled GFP-Nanotrap in buffer A were added. The plate was incubated at room temperature for 45 minutes, after which 2 μL (0.4 μg) of streptavidin-coated donor beads diluted in buffer A were added and incubated in the dark at room temperature for 45 minutes. The ALPHAScreen signal was measured on an Envision Plate Reader (PerkinElmer) according to the manufacturer's recommended settings (λexc=680 / 30 nm for 0.18 sec, λem=570 / 100 nm after 37 ms). The resulting bell-shaped curve indicates a positive interaction, while a flat line reflects a lack of interaction between the proteins. Each protein pair was measured in triplicate.

[0127] The binding index was calculated as follows:

number

[0128] I is the maximum signal level (top of the Hook effect curve) and Ineg is the minimum (background) signal level. Signals were normalized to the Iref signal obtained for the strongest interaction. Protein-protein interactions (IC 50Assays for disruption of GFP were performed by expressing protein pairs in LTE and incubating for 1 h with a dilution range or a single concentration of test compound in buffer B (0.3-300 μM or 50 μM) or DMSO (0.7% DMSO final). The interaction percentages are:

number

[0129] Co-immunoprecipitation (co-IP). Co-immunoprecipitation was performed as previously described ( Sierecki et al., 2014 ). Briefly, SOX18-Cherry-cMyc was co-expressed in a Leishmania tarentolae cell-free protein expression system together with GFP-RBPJ, GFP-MEF2C or GFP constructs as negative control baits. NaCl was added to the expressed protein (200 mM) and the sample was incubated with 10 μL of GFP-Nanotrap coated beads (NHS-activated Sepharose coupled with MBP-GFP-Nanotrap) for 30 min at 4° C. with gentle mixing by rotation. The beads were then washed six times with 200 μL of wash buffer (PBS with 0.1% Triton X-100 and 200 mM NaCl). Proteins were released from the beads by heating at 72°C for 3 min in 15 μL of 2xNuPAGE LDS loading buffer and separated on a NuPage Novex 4-12% gel (Life Technologies, Australia). Gels were scanned for GFP and Cherry fluorescence using a ChemiDoc MP System (Bio-Rad, Australia).

[0130] Critical Micelle Concentration (CMC) The critical micelle concentration was determined based on the incorporation of a fluorescent agent, 1,6-diphenyl-1,3,5-hexatriene (DPH), into the micelles ( Chattopadhyay and London, 1984 ). Small molecules and positive controls (mild detergent Triton X100 and anionic detergent SDS) were cascade diluted from 1000 μM to 0.1 μM in low binding 96-well plates. Dilutions were made in 200 mM NaCl or FP buffer. DPH was supplemented at 5 μM in black 384-well plates. After 30 min of incubation at room temperature, the fluorescence intensity (λexc=360 nm, λem=430 nm) was measured and the CMC shift was estimated graphically.

[0131] Cytotoxicity assay. Cytotoxicity was determined using Alamar Blue as previously described (McMillian et al., 2002). COS-7 cells were seeded at 7000 cells per well in black walled clear bottom 96 well plates in DMEM medium with 10% FBS (Life Technologies Australia). ATCC HepG2 and HEK293 cell lines were seeded at 5000 cells per well in black-walled, clear-bottom 384-well cell culture plates in DMEM with 1% FBS. The cells were cultured at 37° C. and 5% CO 2 for 24 hours. Serial dilutions of compounds were added and the final DMSO concentration was adjusted to 0.5% v / v. The cells were further incubated for 24 h. 1% Triton X-100 was used as a negative control and 0.5% DMSO was used as a positive control. After 2 h incubation at 37°C, 5 μM Alamar Blue was added to each well and fluorescence was measured (λexc=560 nm, λem=590 nm). Data were analyzed using Prism software.

[0132] Direct DNA binding assay using surface plasmon resonance (SPR) Compounds were tested in 1% v / v DMSO in HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% v / v polysorbate 20, pH 7.4). The same buffer supplemented with 1% v / v DMSO was used as the mobile phase. The DNA minor groove binder, DAPI (4',6-diamidino-2-phenylindole), the DNA intercalator and minor groove binder, actinomycin D, and the DNA intercalator, ethidium bromide, were used as positive controls. Biotinylated (one tag per probe) double-stranded DNA probes were prepared using standard annealing routines for single-stranded antiparallel DNA probes purchased from Geneworks (100°C for 5 min, room temperature overnight, and storage at 20°C) and immobilized on a CM5-SA streptavidin chip according to the manufacturer's recommendations. The flow rate of the running buffer was set at 25 μL / min, and cycles consisted of, for compounds and actinomycin D, 4 min of association, 4 min of dissociation, followed by a 10 s pulse of 10 mM Gly-HCl, pH 2.5, for regeneration, and 1 min of stabilization. DAPI did not require any regeneration, whereas ethidium bromide required a 40 second pulse of 0.5% v / v SDS at 25 μL / min prior to stabilization for regeneration. All sample and control cycles were performed in triplicate. DMSO calibration was performed according to the manufacturer's recommendations. After each injection, an additional wash of the flow system was performed with 50% v / v DMSO to avoid carryover. Experiments were performed on a Biacore T200 (GE Healthcare, USA) and one flow cell was kept as a reference.

[0133] Direct protein binding assay (heat aggregation). Differential static light scattering studies were performed on a Harbinger Biotech StarGazer using mouse SOX18-HMG(109aa) in the presence and absence of either Prox1-DNA or putative small molecule ligands. Initial experiments were performed to evaluate the concentration of compound at which the change in aggregation temperature was no longer concentration dependent. Final concentrations used ranged from 500 μM (Sm4 and Sm14) to 1.5 mM (Sm5), depending on the need to limit the concentration of DMSO to 3%. The 17bp Prox1-DNA oligonucleotide was used at a final concentration of 10 μM. Binding was performed in triplicate and detected by a >2° C. increase in Tagg (aggregation temperature) in the presence of ligand. Tagg was measured once using the same protein batch. Reactions were carried out in Tris-NaCl buffer (10 mM Tris-HCl, 150 mM NaCl, pH 8) with 3% v / v DMSO in a final reaction volume of 45 μL at a mouse SOX18-HMG concentration of 154 μM. These were incubated at room temperature for 1 hour before measurement. Proteins were heated from 25°C to 80°C at a rate of 1°C / min. The total intensity was plotted versus temperature for each sample and fit to the Boltzmann equation by nonlinear regression.

[0134] In silico docking and molecular dynamics Ligand-protein docking In silico docking of Sm4 into the SOX18 / DNA complex was performed using LeadIT / FlexX (BioSolveIT, Germany). Docking was performed by removing all water molecules from the structure of SOX18-HMG / Prox1-DNA (pdb:4Y60) and defining the entire protein / complex as a possible binding site. The best 20 docking poses of Sm4 were analyzed and classified into four clusters. Because SOX18 / DNA does not contain a conventional binding pocket, each pose cluster was further verified by 200 ns long MD simulations. MD simulations were performed using the complete SOX18 / DNA structure with Sm4 in its different binding poses. Analysis of the MD simulations revealed that three of the poses were unstable and, with Sm4, destroyed their interactions with the protein in the first 3–14 ns of the simulation and remained in the aqueous solvent for the remainder of the simulation. Only one of the poses generated by the MD simulation produced a stable binding pose of Sm4 during the entire 200 ns simulation. Similarly, docking and MD simulations were performed with Sm4 and SOX18 without DNA. However, none of the 4-pose clusters produced stable binding orientations during MD simulations. For comparison, MD simulations were performed on SOX18 / DNA without Sm4 and SOX18 without DNA, which produced similar conformational and dynamical behavior to the structure with the Sm4 ligand.

[0135] Protein-protein docking Protein-protein docking between the Notch1 transcription complex and SOX18 was performed using the ClusPro online server version (cluspro.bu.edu). For the structures of the Notch1 transcription complex and SOX18-HMG, pdb:3V79 and pdb:4Y60 were used, respectively. The DNA molecules were removed before docking because ClusPro cannot process them, and were reconstructed after docking. Docking solutions with clashing DNA molecules were rejected. The obtained top docking pose was used as the starting conformation in a 50 ns long MD simulation to optimize the docking pose and verify the stability of the multiprotein complex.

[0136] MD simulation Any MD simulations were performed using the AMBER MD software “pmemd” using the ff99SB force field for proteins and DNA, TIP3 for potential water, and applying periodic boundary conditions (NTP), the particle mesh Ewald (PME) method for long-range electrostatic interactions, isotropic pressure coupling and Langevin thermostat (gamma_ln=1 / ps) for temperature coupling. Simulations were performed using a 2 fs step size and the SHAKE algorithm was used to constrain bonds involving hydrogen. For MD simulations with Sm4, force field parameters for the ligands were calculated using Antechamber from the AMBER package. All MD simulations were performed by minimizing the structures and then equilibrating them by slowly decreasing the positional restraints over 5 ns. Each simulation was performed three times using different random numbers for the assignment of initial velocities.

[0137] COX1 / COX2 enzyme assay COX inhibitory activity was measured using COX1 and COX2 inhibitor screening assay kits from Cayman Chemical Company (Ref# 701090 and 701080). All compounds were tested in quadruplicate at a single 200 μM concentration in 2% v / v final DMSO. Compounds were pre-incubated with ovine COX1 or human COX2 for 10 min at 37° C., followed by an additional 3 min incubation with the COX substrate arachidonic acid. The reaction was quenched by the addition of concentrated hydrochloric acid. Prostanoid standard curves were prepared and enzyme immunoassays were performed as described by the manufacturer. A DMSO control, a 100% inhibition control with heat-inactivated COX enzyme, and a 200 μM meclofenamic acid positive control (a potent non-selective COX1 / 2 inhibitor) were included for reference. Prostanoid standard values ​​were plotted as logit(B / B0) versus log concentration and fitted to linear regression using GraphPad Prism version 6.0. Each sample concentration was calculated using a linear fit of the standard curve.

[0138] SOX18 single molecule tracking FIG. 24B shows the experimental workflow, including two-dimensional tracking of molecular trajectories and analysis using MATLAB, as outlined in Chen et al. (Cell 156, 1274-1285; 2014). We note that the immobile DNA binding fraction (%, shown in the pie chart) is of two types, specific and nonspecific, depending on the residence time at one and the same DNA site; if the residence time is short (less than 1 s on average), this is considered as nonspecific binding (i.e., transient binding to random DNA sites), and if it is long (more than 5-6 s on average), this is considered as specific binding (i.e., longer binding to target DNA sites with transcriptional effects). The residence times of the immobile DNA-binding moieties (shown as bar graphs) are also of two types, specific and nonspecific: the length of time in seconds that SOX18 molecules are nonspecifically (<1 s on average) or specifically (>5–6 s on average) bound to DNA. Single molecule tracking is performed after transfection of HeLa cells with a SOX18-Halotag reporter construct. This expression vector allows us to detect single molecules of SOX18 protein after addition of a ligand that becomes fluorescent after enzymatic treatment with the Halotag system. Real-time imaging is performed using a modified version of TIRF microscopy (HiLo) using a ZEISS ELYRA super-resolution microscope.

[0139] result Screening of natural products for inhibition of SOX18-DNA binding A marine extract library was screened for inhibitors of SOX18 protein (full-length Mus musculus) binding to DNA using a fluorescence polarization-based assay (FP). We selected the SOX18 direct target, a fluorescently labeled oligonucleotide carrying the consensus SOX motif found in the first intron of the Prox1 gene ( Francois et al., 2008 ) ( Fig. 1A ). The library contains 2,000 purified metabolites and 2,688 marine extracts, containing over 50,000 structures. This primary screening identified 16 active extracts collected from various phyla, namely, sponges (10), algae (5) and urochordata (1) (hit rate 0.6%, primary screening Z' value = 0.62) (Zhang et al., 1999). Subsequent extract analysis was prioritized based on potency and abundance of biologically active molecules, and the most active extract was derived from the brown alga Caulocystis cephalornithos, which produced two active compounds: 6-undecylsalicylic acid (Sm1) and 6-tridecylsalicylic acid (Sm2) (Figure 1B). Dose-response screens for both Sm1 and Sm2 demonstrated inhibitory effects (IC 50 ) (Figure 1C). Both active compounds contain a salicylic acid skeleton with a large aliphatic group.

[0140] Focused library design and primary screening. In the next step, we designed a small library of analogues to validate the salicylic acid (hydroxylbenzoic acid) active scaffold and study its structure-activity relationship profile. The selection shown in FIG. 2A also included compounds with a similar resorcinol backbone (replacing the carboxylic acid with an additional hydroxyl), as well as a number of approved NSAIDs containing similar salicylic or anthranilic acid backbones (replacing the hydroxyl with an amine). The library was purchased and screened for inhibition of SOX18-DNA binding using the FP assay. In this assay, disruption of high affinity protein-DNA interactions required inhibitor concentrations in the high micromolar range where aggregation can occur, especially for amphiphilic and high log P molecules (Irwin et al., 2015). Therefore, compounds were counter-screened for critical micelle concentration (CMC) to exclude aggregate or micelle forming compounds as false positives (Table 1, columns 2 and 5 and FIG. 2B).

[0141] In the CMC assay, five compounds exhibiting CMCs at 20 and 30 μM were excluded: Sm3, Sm6, Sm7, Sm9, and Sm10 (Table 1, column 2). The others showed no micelle formation up to 1000 μM and were included in the SOX18-DNA binding assay. The CMCs of Sm1 and Sm2 could not be determined due to lack of supply of the compounds. SOX18-DNA binding assay has an IC of less than 1000 μM 50 We identified seven compounds with IC values ​​of approximately 350 μM, two of which, Sm4 and Sm14, were significantly higher than the original hits Sm1 and Sm2 (IC 50 ) with an improved IC of approximately 100 μM 50 values ​​are shown (Table 1, column 1; Fig. 2C). Interestingly, all three anthranilic acid analogues, meclofenamic acid, niflumic acid and flufenamic acid, also showed IC values ​​in the 100–400 μM range. 50 The activity of the IgG1 antibody is shown (Table 1, column 1; Figure 2C).

[0142] To identify possible binding sites for small molecules, the FP assay was repeated with shorter, DNA-binding-centered protein fragments. The DNA-binding domain of SOX TF consists of a 79 amino acid long High Mobility Group (HMG) box. The 109 amino acid long SOX18 fragment (SOX18) corresponds to residues 69-177 (numbering according to mouse SOX18), which includes the HMG box (residues 78-149) and N- and C-terminal flanking sequences of 9 and 28 amino acids, respectively. FP assays using the SOX18

[0109] fragment showed IC values ​​nearly identical to those of full-length SOX18 (data not shown). 50 values, suggesting that small molecules interact with this 109-aa portion of the protein.

[0143] Binding selectivity From a molecular perspective, inhibitors of SOX18-DNA binding may act by interacting directly with DNA or the protein, or at the protein-DNA interface. Although direct binding of small molecules to DNA has been reported for other TFs (Leung et al., 2013), there is the potential for non-specific DNA binding, which may result in genotoxicity, mutagenicity or carcinogenicity. To that end, we developed a direct binding assay to determine whether active compounds interact directly with DNA or proteins. A surface plasmon resonance-based method was developed to analyze the binding of small molecules to biotinylated double-stranded DNA immobilized on the surface of a streptavidin chip. This method measures the on-rate (k), off-rate (koff) and binding constant (KD) and was used to measure binding to two different DNA sequences: SOX binding site consensus DNA, and scrambled DNA. The intercalating agents, ethidium bromide and actinomycin D, and the minor groove binder, 4',6-diamino-2-phenylindole (DAPI), were used as positive controls for non-selective DNA binding. All positive controls showed KD unrelated to the DNA sequence and consistent with the literature. This analysis showed that none of the SOX18 inhibitors showed binding to consensus or scrambled DNA (Figures 3A and 3B).

[0144] To investigate whether the inhibitors interacted directly with the protein, we measured the resulting increase in SOX18 thermostability by assessing the shift of the protein unfolding equilibrium to higher temperatures (Shrake and Ross, 1992; Shrake and Ross, 1990; Brandts and Lin, 1990; Fukada et al., 1983). To this end, we used static light scattering as a readout of protein-inhibitor complex aggregation ( Mittal et al., 2014 ; Senisterra et al., 2006 ; Senisterra et al., 2008 ; Senisterra and Finerty, 2009 ; Senisterra et al., 2012 ). Thermostability was measured using the HMG-only SOX18

[0109] fragment and a DNA probe decorated with a SOX motif as positive controls. Sm4, Sm5 and Sm14 were tested at concentrations that saturated all potential binding sites of SOX18, 500 μM for Sm4 and Sm14, and 1.5 mM for Sm5, respectively. At these maximal ligand-bound conditions, temperature-dependent protein aggregation was no longer limited by binding site occupancy and was measured until a plateau was reached. Each inhibitor showed an increase in Tagg by more than 3°C, consistent with a direct interaction of the inhibitors with the protein (Figure 3C). Taken together from both binding studies, the results indicate that the small molecule inhibitor interacts with the SOX18 protein without directly interacting with DNA. In addition, the combined data from the FP and thermostability assays suggest that the inhibitor-protein interaction site is located within or in close proximity to the SOX18-HMG box.

[0145] SOX DNA binding inhibition selectivity The DNA-binding domain of all SOX proteins is highly conserved and shares 46% sequence identity with the HMG domain of the mammalian testis-determinant SRY ( Bowles et al., 2000 ; Gubbay et al., 1990 ), whereas the remaining domains of SOX TFs adjacent to the HMG domain show lower levels of similarity. To study the selectivity of SOX18 inhibitors, HMG-only protein fragments from different SOX proteins were used in a DNA-binding FP-based assay using a fluorescently labeled oligonucleotide bearing the known SOX motif, 5′AACAAT3′. The distinct SOX TFs include: SOX2 (group B), SOX11 (group C), SOX6 (group D), SOX9 (group E), SOX18 (group F) and SOX15 (group G). The most active inhibitor, Sm4, was evaluated against all the different SOX TFs and showed DNA binding inhibition in all cases (IC 50 (~200-300 μM) and has a slight preference for SOX18 and SOX15 (IC 50 200-220 μM versus 270-310 μM for the others), suggesting that the inhibitors are nonselective for SOX TFs with respect to disruption in DNA binding (FIG. 3D).

[0146] Off-target analysis COX Inhibition Salicylates are an important class of NSAIDs that act via direct or indirect inhibition of cyclooxygenase (COX)-dependent production of proinflammatory prostaglandins (Pillinger et al., 1998). In this study, we identified SOX18 inhibitors with structural similarity to COX inhibitors, and to study any functional overlap between NSAIDs and novel SOX18 inhibitors, we included structurally similar NSAIDs in the SOX18 study. Similarly, we investigated whether novel SOX18 inhibitors inhibit COX1 / 2 enzyme activity. The COX-1 and COX-2 inhibitory effects of Sm4, Sm5, Sm8, Sm11, Sm12, Sm13 and Sm14 were evaluated using a commercial COX-1 / 2 ELISA assay with meclofenamic acid as a positive control. None of the SOX18 inhibitors exhibited COX-1 or COX-2 inhibitory activity up to a concentration of 200 μM ( Figures S1A, S1B ).

[0147] Off-target profiling We further investigated potential SOX18-independent effects of our lead Sm4 using the Eurofins-CEREP / Panlabs panel of radioligand binding assays against a variety of receptors, enzymes and transporters, including G-protein coupled receptors (GPCRs), ion channels, membrane receptors, kinase and non-kinase enzymes, and nuclear receptors, which are involved in a wide range of potential off-target effects (Table 4). A number of epigenetic modifiers were also examined using a series of recombinant-enzyme fluorometric assays. No significant inhibition (>50%) was observed at 10 μM, indicating Sm4 selectivity and potential for further drug development.

[0148] SOX18 protein-protein interactions The highly conserved HMG domain of SOX transcription factors has been reported to be involved in both protein-DNA and protein-protein interactions ( Agresti and Bianchi, 2003 ; Prokop et al., 2012 ; Huang et al., 2015 ). Thus, compounds that bind directly to or in close proximity to the HMG domain have the potential to modulate both SOX18-DNA and SOX18-protein interactions, either directly or through allosteric changes to the conformation of the SOX18 protein. To study the possibility that our small molecules modulate SOX18-protein interactions, we selected two SOX18 PPIs known to be involved in transcriptional regulation in endothelial cells: MEF2C has been reported to bind to SOX18 in GST pull-down assays (Hosking et al., 2001), and RBPJ has been reported to genetically interact with SOX18, although direct binding has yet to be identified ( Sacilotto et al., 2013 ). In addition, XRCC6 (ATP-dependent DNA helicase II) was selected as a non-binding partner as a negative control.

[0149] We used a cell-free expression system to express tagged proteins and analyzed PPI inhibition, and combined this with the ALPHAScreen technology (Amplified Luminescent Proximity Homogeneous Assay), allowing us to measure the propinquity of the tagged proteins (Sierecki et al., 2013). This approach confirmed a direct pairwise interaction between SOX18 and its known partner MEF2C, and revealed a direct PPI between SOX18 and RBPJ (Figure 4A, left panel). The direct physical interaction was further verified using standard co-immunoprecipitation (FIG. 4A, right panel). Next, we investigated the ability of our most potent small compound, Sm4, as well as meclofenamic acid, niflumic acid, and flufenamic acid, to disrupt SOX18-MEF2C or SOX18-RBPJ interactions. Sm4 disrupted SOX18-RBPJ interaction with an IC50 of 42.3 μM, but had no effect on SOX18-MEF2C interaction (Figure 4B, upper left and upper right panels). Conversely, flufenamic acid disrupted the SOX18-MEF2C interaction (IC of 29.1 μM). 50 ), whereas SOX18-RBPJ interaction was only slightly disrupted (IC of ∼444 μM 50 ) (Figure 4B, upper left and lower right panels). Other NSAIDs had little or no effect against any of the PPIs.

[0150] SAR Library The structure-activity relationships (SAR) of salicylic acid-type inhibitors of SOX18-DNA binding and SOX18 / RBPJ PPI were studied in more detail using separate libraries of analogues. This library was designed to query the significance of several unique features of Sm4 and other salicylates, including: Electron density of the salicylate aromatic ring, The significance of the two acid hydrogens in the β-hydroxyl carboxylic acid motif, saturated or ethylenic linkages with lipophilic tails, and Structure and lipophilicity of the lipophilic tail. We synthesized 30 analogs, Sm15 to Sm44 (Figure 5), and screened them for inhibition of DNA binding to the HMG-only SOX18

[0109] fragment and for disruption of the SOX18-RBPJ interaction (upper and lower panels). In addition, a number of these analogs (i.e., Sm4, Sm17-Sm24, Sm26, Sm31, Sm34, Sm37 and Sm40-Sm42) were also tested for disruption of the SOX18-SOX18 homodimerization interaction using the ALPHAScreen assay described above. As shown in FIG. 5, Sm4, Sm17-Sm23, Sm26, Sm31, Sm34, Sm37, Sm40 and Sm41 showed some inhibitory activity associated with SOX18-SOX18 homodimerization at a concentration of 5 uM. This library was also screened for general cytotoxicity against two cell lines, HEK293 and HepG2, to assess their exploitability (Table 3).

[0151] Potential PAINS (Pan Assay Interference Compounds) chemical moieties common to a variety of promiscuous frequent hitters (which act as false positives in many biochemical high-throughput screens) were analyzed using the in silico predictor “FAF-Drugs3” (http: / / fafdrugs3.mti.univ-paris-diderot.fr / ) (Baell and Holloway, 2010; Lagorce et al., 2008). In total, only three compounds were flagged in the PAINS moiety (Sm14, Sm40 and Sm44). Sm14 contains a methylene-thiazolone motif, or a reactive α,β-unsaturated carbonyl group, whereas both Sm40 and Sm44 contain oxidatively labile catechol groups (Table 2). Sm40 and Sm44 were not active in the FP assay, while Sm14 was not followed beyond the binding assay. In addition, the new libraries were analyzed for potential aggregators using the "Aggregator Advisor" database, but none showed similarity to known aggregators and all exhibited moderate lipophilicity with logP values ​​below 5.8 (Table 3).

[0152] SAR for inhibition of SOX18-DNA binding The activity data showed some clear SAR for inhibition of SOX18-DNA binding, with any etherification, esterification, or amidation of either or both of the β-hydroxyl and / or carboxylic acid reducing or eliminating activity. Interestingly, replacement of the carboxylic acid with a hydroxyl is tolerated, albeit reducing the inhibitory activity of the compound. Similarly, salicylates para-substituted with small electron donating groups show similar activity and are tolerated; however, the reduction in acidity appears to increase cytotoxicity. In the case of aromatic tails, replacement of naphthyl with phenyl (Sm22) completely abolished all activity. From this small library, only Sm20, an unsaturated analogue of Sm4, exhibited SOX18-DNA binding inhibitory activity and low cytotoxicity, similar to Sm4 (FIG. 5).

[0153] SAR for inhibition of SOX18-RBPJ protein-protein binding Analogs were initially tested at 50 μM. Compounds showing greater than 50% inhibition were then retested at a lower concentration of 5 μM. Activity is compared to control levels of SOX18-RBPJ in the presence of vehicle solvent with or without the lead compound Sm4, which is also tested at both concentrations. The IC shown in Figure 4B 50 As expected from the plot (upper right panel), inhibition by 50 μM Sm4 is nearly complete (11.9±5.6%, FIG. 5, lower panel) and marginal at 5 μM. At the high concentration of 50 μM, half of all tested compounds showed strong activity, but only Sm18, Sm19, Sm26, Sm34 and Sm40 were still highly active at 5 μM, with Sm26 remaining moderately active. Interestingly, none of these five potent PPI inhibitors inhibited protein-DNA binding.

[0154] The pattern of inhibition of the SOX18-RBPJ protein-protein interaction is less clear than that of inhibition of the SOX18-DNA interaction. Several of the vinylnaphthalene-containing compounds are active in PPI inhibition; however, it is not clear whether the activity is due to increased rigidity of the linker or to the activity of the vinyl-aromatic group as a Michael acceptor. A defining feature of this library is that free carboxylates are not required for PPI activity, as diethylamide or polyhydroxyl / methoxy-containing compounds show PPI inhibition at 50 μM, but do not show inhibition of DNA binding. Finally, there is little overlap between PPI and DNA binding inhibition, with the exception of Sm4 and Sm20, which inhibit both DNA and PPI.

[0155] structural research The three-dimensional structure of the mouse SOX18-HMG domain bound to DNA containing a SOX motif was recently determined by X-ray crystallography ( Klaus et al., 2016 ) and shows high similarity to other HMG domains. However, attempts to co-crystallize the SOX18 HMG domain bound to DNA in the presence of Sm4 failed to identify the inhibitor binding pocket, as no electron density for the inhibitor was detectable. This could be due to the protein / DNA disruption properties of Sm4. To evaluate the possible binding site of Sm4, we employed in silico docking and molecular dynamics calculations using the SOX18 / DNA crystal structure. In the absence of a defined binding pocket within the SOX18-HMG domain, in silico docking generated several possible binding poses, which were further validated by molecular dynamics (MD) simulations. These simulations identified one binding pose that remained stable for the entire simulation time of 200 ns. In comparison, in all other poses, the inhibitor disrupted its protein interactions after 3–14 ns and remained in the surrounding solvent without protein contacts. Similarly, using the SOX18-HMG structure without DNA, no stable binding pose of Sm4 was found.

[0156] The stable binding pose of Sm4 in the SOX18 / DNA structure places the inhibitor in a solvent-accessible pocket between the protein and DNA, which is otherwise occupied by water molecules in the X-ray crystal structure. The main polar interactions of Sm4 are with Arg136 and Lys147, which exchanges its interactions with dG15 and some induces a conformational change to His143, rotating its side chain towards Sm4 (Figure 6A,B). However, no other major conformational changes could be observed that would directly explain the DNA binding inhibition mode of Sm4.

[0157] To study the possible protein-protein interaction sites of SOX18, we used in silico protein-protein docking combined with MD simulations to build a complex model of SOX18 / DNA and its protein partner RBPJ. In the case of RBPJ, we used the X-ray crystal structure of part of the human Notch transcription complex, solved in 2012 (Choi et al., 2012). This portion contains an ankyrin (ANK) repeat domain bound to the coactivator MAML1, an RBPJ-J-associated molecule (RAM) domain from the Notch intracellular domain, and the transcription factor RBPJ bound to its consensus DNA. Docking of the SOX18 / DNA structure into this structure of the Notch transcription complex and subsequent MD simulations for optimization yielded the complex model shown in FIG. 6C. This model indicates that the RBPJ / SOX18 complex may be mediated by the HMG domain and can form a protein complex unhindered by both DNA molecules. Indeed, both DNA strands from RBPJ and SOX18 are oriented approximately parallel to each other, similar to the DNA orientation relative to the nucleosome. In addition, both the C- and N-terminal tails of the HMG domain are oriented towards the solvent, allowing addition of the missing SOX18 domain without directly interfering with the RBPJ complex.

[0158] The interaction between SOX18 and RBPJ is provided by residues from the C-terminal part of helix 3 and the C-terminal tail of the HMG domain (residues Gln138, Arg141, Asp142, and His143). This protein-protein interface is thereby opposite to the DNA binding interface of the region. Mapping of the putative binding site of Sm4 on the RBPJ / SOX18 complex positioned the inhibitor closely within the SOX18 DNA-binding region in helix-3 and the C-terminal tail, opposite its main protein-protein interface, suggesting that Sm4 binding may perturb both protein-protein and protein-DNA interactions.

[0159] Regulation of SOX18 transcriptional activity To further evaluate the functional effects of SOX18 inhibitors, we used an in vitro cell-based reporter system as a readout of SOX18 transcriptional activity. COS-7 cells were transfected with a construct containing a Vcam-1 promoter fragment fused to a luciferase reporter gene and a SOX18 expression vector. Sm4, our lead compound in the context of PPI disruption specificity, was tested in this cell-based assay along with meclofenamic acid, niflumic acid and flufenamic acid. Of these four small molecules, Sm4 showed the most effective inhibition of SOX18 transcriptional activity, with an IC 50 The value was 5.2 μM (Figure 6D). Cytotoxicity of meclofenamic acid and flufenamic acid was reached before any concentration-dependent SOX18 inhibition could be observed. All other test compounds showed lower potency (20 μM <IC 50 <50 μM, Table 1, column 3).

[0160] The observation that Sm4 selectively perturbs specific PPIs at a concentration range similar to that required to inhibit their transcriptional activity in vitro suggests that the mode of action of this small compound may be through interference with protein partner recruitment.

[0161] Assessment of SOX18 target binding by SM4 using single molecule tracking (SMT) By using the SMT technique, the inventors are able to visualize the search pattern of SOX18 protein for its target genes on chromatin in real time in living cell nuclei with single molecule resolution. The fact that it is possible to visualize the perturbation of SM4 on SOX18 chromatin binding dynamics clearly indicates SM4 on-target involvement. This effect is observed at concentrations that lack any cytotoxicity. The effect of SM4 caused SOX18 to reside longer at specific sites on chromatin, and this change in protein dynamics could be the result of alterations in SOX18 protein-protein interactions that were impaired by SM4 (as previously shown by ALPHAScreen assays). The mode of action of transcription factors is driven by a code of protein-protein interactions that dictates gene target selectivity. If this code is altered, transcription factor activity is abolished.

[0162] Consideration Transcription factors are proteins that have a DNA-binding domain, multiple protein partners, and, in some cases, even endogenous ligands. The concept that TF activity depends on this type of interaction opens up different avenues for discovering molecules that regulate its function, e.g., screening for inhibitors of protein-DNA or protein-protein interactions. Although a large amount of information exists regarding the genetic pathways in which TFs are involved, little has been reported regarding their molecular mode of action and, more specifically, the recruitment of multiple protein partners. Thus, even though the DNA-binding domain is highly conserved within the TF family and constitutes a region with low potential for selection, screening for DNA-binding inhibitors has, until recently, offered the main option for finding TF modulators.

[0163] In this study, we used a high-throughput DNA-binding assay to screen a chemically diverse natural product library to identify compounds capable of inhibiting DNA binding of the transcription factor SOX18. The screen identified two compounds of similar structure, both possessing a salicylic acid core and a lipophilic tail. A focused library designed around the two active compounds identified a broader range of similar compounds with varying degrees of activity, demonstrating that these compounds form a cluster of SOX18 DNA-binding inhibitors. Using this focused library, we further demonstrated that the inhibitory activity was due to binding of the small compounds to the protein and not to the DNA itself. The active molecule interacts with the SOX18 protein and increases its thermal stability upon binding. In addition, using either the SOX18 full-length or HMG box-only protein, we demonstrated that the compounds interact directly with or immediately adjacent to the DNA-binding domain.

[0164] We have previously argued that using DNA binding disruption as a filter yields compounds with low selectivity between SOX transcription factors due to the high level of sequence conservation of the HMG-boxes. Consistent with this, our lead compound, Sm4, was able to disrupt the DNA-binding activity of a wide range of HMG-boxes from various SOX proteins when used at high concentrations (200-300 μM). The HMG box of SOX proteins consists of three α-helices, two of which provide the main interfaces for DNA binding. However, the SOX9 HMG box has also been reported to be involved in protein-protein interactions ( Huang et al., 2015 ; Agresti and Bianchi, 2003 ; Prokop et al., 2012 ), and the third α-helix has been proposed as the main interface for partner proteins. In this study, we applied an in vitro method of protein-protein interaction (PPI) detection to study the disruption of TF protein partner recruitment. Direct protein-protein interaction of the transcription factor SOX18 has only been reported for MEF2C ( Hosking et al., 2001 ), whereas genetic interaction with RBPJ has only been shown in the transcriptional promotion of the Dll4 gene ( Sacilotto et al., 2013 ). Both proteins show direct binding to SOX18 in cell-free / ALPHASreen and co-IP assays. Importantly, some small molecules disrupt specific PPIs differently. Thereby, Sm4, which has a salicylic acid backbone, is more selective in disrupting the SOX18 / RBPJ complex, whereas flufenamic acid, which has an anthranilic acid backbone, is more selective with respect to the SOX18 / MEF2C complex. Furthermore, in silico docking provides a putative binding pocket for Sm4 wedged between the DNA and the third helix of the protein, close to the C-terminal tail of the HMG box. This location suggests that inhibitors such as Sm4 can alter the conformation of the SOX18 protein not only to affect DNA binding but also to affect its interaction surfaces with protein partners such as RBPJ.

[0165] Furthermore, studies of the effects of small compounds on SOX18 transcriptional activity revealed that Sm4 could block SOX18-dependent Vcam-1 promoter activity when fused to a luciferase reporter gene. Flufenamic acid has minimal effect on blocking SOX18 transcription. This reporter assay was performed in COS-7 cells transfected with both Sox18 and luciferase expression vectors, thus limiting interpretation of disruptions of potential SOX18 endogenous partner recruitment. Nonetheless, inhibition of SOX18-regulated transcription by Sm4 is a clear indication that small molecules can interfere with transcription factor activity within a cell-based environment.

[0166] Synthesis and screening of the expanded library further revealed several clear structure-activity relationships for inhibition of SOX18 / DNA binding. Some variation in the lipophilic tail and its linker is permitted, but both the hydroxyl or carboxylic acid groups must retain their hydrogen bond donating ability, as any esters, ethers or amides will abolish activity. Varying the carboxylic acid with a para-substituted electron donating group had little effect, as did replacing the acid with a hydroxyl (resorcinol backbone), and both retained their ability to inhibit SOX18 DNA binding. Compounds with anthranilic acid backbone were selected as an extension of the chemical similarity of the salicylic acid backbone to NSAID compounds. Studies have shown that SOX18 inhibitors have no inhibitory activity against COX1 or COX2, although some NSAID compounds show SOX18 DNA binding inhibition. However, differences in SOX18-protein binding inhibition (SOX18-MEF2C inhibition instead of SOX18-RBPJ) suggest different binding or modes of action.

[0167] The efficacy of a compound to inhibit the transcriptional activity of a TF depends on the concentration of both the TF and the compound in the nucleus. Although the concentration of TF can reach near millimolar levels in the nucleus (Chen et al., 2014), compound concentration depends on its ability to distribute across both the cellular and nuclear membranes. In the early stages of drug discovery, IC 50 Measuring the α- and β-direction of ... However, for further drug optimization, predictive models or effective inhibitory concentrations (IC 50 Penetration of compounds into the nucleus, either by cell-based assays measuring nuclei or by nuclease-specific cell ...

[0168] Another consideration that needs to be made when developing a TF inhibitor is which PPIs are predominantly affected by the compound. Protein-protein interactions, including those between TFs, are relatively weak. For example, the interaction between p32 and HDM2 has a KD in the low-to-mid micromolar range ( Dawson et al., 2003 ; Chen et al., 2013 ). In comparison, antibody-antigen interactions or interactions between endogenous peptide ligands and receptors (e.g., EGF-EGFR) are much stronger, with KDs in the low nanomolar to high picomolar range (Mian et al., 1991; Lax et al., 1988). Similarly, interactions between proteins and DNA are in the low nanomolar range, due in large part to strong electrostatic interactions between negatively charged DNA and the usually positively charged DNA binding domains. Sm4 can inhibit both SOX18 / DNA and SOX18 / RBPJ interactions, but the inhibitory effect is higher for weaker PPIs.

[0169] An important consideration in the development of TF inhibitors is the ability to selectively inhibit PPIs, especially as TFs are capable of recruiting a half-dozen different protein partners (Gamper and Roeder, 2008). Even though TFs are intrinsically disordered ( Wright and Dyson, 2015 ), these proteins exhibit domain modularity with respect to distinct protein-protein interfaces ( Reichmann et al., 2005 ). This suggests that some interactions share structural similarities while activating distinct downstream pathways. As with other regulatory proteins and enzymes such as kinases, the selectivity profile of TF protein-protein inhibition needs to be considered. Although blockade of all PPIs may not be desirable, it is possible that maximal efficacy will not be achieved by single PPI inhibition but by simultaneously inhibiting the recruitment of a select subset of protein partners.

[0170] In conclusion, this study identified salicylic acid derivatives as key pharmacophores for SOX18 inhibition and identified Sm4 as a lead compound. Further drug optimization should be performed following clues from both protein-DNA binding and PPI assays to further refine selectivity and potency.

[0171] [Table 1]

[0172] Referring to Table 1 above, in the first column, compound FP IC50s were estimated using a variable Hill slope curve fit. Different concentration ranges were tested in the FP-based DNA binding competition assay (0.2-200 uM, 10-500 uM, 10 uM-3 mM) including DMSO concentrations ranging from 0-3.33% v / v. The experiment was performed in three independent replicates. The second column summarizes the threshold concentrations at which compounds Sm1-14 initiate the formation of micelles in saline (200 mM NaCl) or fluorescence polarization buffer (30 mM HEPES pH 7.5, 100 mM KCl, 40 mM NaCl, 10 mM NH4OAc, 10 mM guanidinium, 2 mM MgCl2, 0.5 mM EDTA, 0.01% NP-40). The third and fourth columns show the IC of cell-based luciferase SOX18-dependent transactivation in COS7 fibroblasts for all active compounds. 50 - and cytotoxicity - CC 50 -The 50% inhibitory concentrations are summarized. In the final column, we used “Aggregator Advisor” (Irwin et al., 2015) to predict aggregators based on their physical properties (CLog P>3) and similarity to a robust library of known aggregators—12,600 compounds. * : Compounds similar to known aggregators, #: Not similar to any known aggregator, but high risk due to "high" LogP : no predicted risk of aggregation).

[0173] [Table 2]

[0174] [Table 3]

[0175] [Table 4]

[0176] [Table 5] JPEG0007579057000029.jpg213170

[0177] Chemical analysis of compounds Sm15-Sm44 The purity of the compounds was determined by HPLC (ESI-MS / UV / ELSD) and their molecular formulas were determined by HighRes MS (ESI microTOF-LC). 1 H and 13 The structure was confirmed using C-NMR experiments (see Appendix A).

[0178] References AGRESTI, A. & BIANCHI, ME2003. HMGB proteins and gene expression. Curr Opin Genet Dev, 13, 170-8. BAELL,JB&HOLLOWAY,GA2010.New substructure filters for removal of pan assay interference compounds(PAINS) from screening libraries and for their exclusion in bioassays.J Med Chem,53,2719-40. BASS,A.J.,WATANABE,H.,MERMEL,C.H.,YU,S.,PERNER,S.,VERHAAK,R.G.,KIM,S.Y.,WARDWELL,L.,TAMAYO,P.,GAT-VIKS,I.,et al.2009.SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.Nat Genet,41,1238-42. BOWLES,J.,SCHEPERS,G.& KOOPMAN,P.2000.Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators.Dev Biol,227,239-55. BOYADJIEV,S.A.& JABS,E.W.2000.Online Mendelian Inheritance in Man(OMIM)as a knowledgebase forHuman developmental disorders.Clin Genet,57,253-66. BRANDTS,J.F.& LIN,L.N.1990.Study of strong to ultratight protein interactions using differential scanning calorimetry.Biochemistry,29,6927-40. CERMENATI,S.,MOLERI,S.,CIMBRO,S.,CORTI,P.,DEL GIACCO,L.,AMODEO,R.,DEJANA,E.,KOOPMAN,P.,COTELLI,F.& BELTRAME,M.2008.Sox18 and Sox7 play redundant roles in vascular development.Blood,111,2657-66. CHATTOPADHYAY,A.& LONDON,E.1984.Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge.Anal Biochem,139,408-12. CHEN,J.,SAWYER,N.& REGAN,L.2013.Protein-protein interactions:General trends in the relationship between binding affinity and interfacial buried surface area.Protein Science,22,510-515. CHEN,J.,ZHANG,Z.,LI,L.,CHEN,B.C.,REVYAKIN,A.,HAJJ,B.,LEGANT,W.,DAHAN,M.,LIONNET,T.,BETZIG,E.,et al.2014.Single-molecule dynamics of enhanceosome assembly in embryonic stem cells.Cell,156,1274-85. CHOI,S.H.,WALES,T.E.,NAM,Y.,O’DONOVAN,D.J.,SLIZ,P.,ENGEN,J.R.& BLACKLOW,S.C.2012.Conformational locking upon cooperative assembly of notch transcription complexes.Structure,20,340-9. DARNELL,J.E.,JR.2002.Transcription factors as targets for cancer therapy.Nat Rev Cancer,2,740-9. DAWSON,R.,MULLER,L.,DEHNER,A.,KLEIN,C.,KESSLER,H.& BUCHNER,J.2003.The N-terminal domain of p53 is natively unfolded.J Mol Biol,332,1131-41. DUONG,T.,KOLTOWSKA,K.,PICHOL-THIEVEND,C.,LE GUEN,L.,FONTAINE,F.,SMITH,K.A.,TRUONG,V.,SKOCZYLAS,R.,STACKER,S.A.,ACHEN,M.G.,et al.2014.VEGFD regulates blood vascular development by modulating SOX18 activity.Blood,123,1102-12. FEHER,M.& SCHMIDT,J.M.2003.Property distributions:differences between drugs,natural products,and molecules from combinatorial chemistry.J Chem Inf Comput Sci,43,218-27. FILIPPAKOPOULOS,P.,QI,J.,PICAUD,S.,SHEN,Y.,SMITH,W.B.,FEDOROV,O.,MORSE,E.M.,KEATES,T.,HICKMAN,T.T.,FELLETAR,I.,et al.2010.Selective inhibition of BET bromodomains.Nature,468,1067-73. FONTAINE,F.,OVERMAN,J.& FRANCOIS,M.2015.Pharmacological manipulation of transcription factor protein-protein interactions:opportunities and obstacles.Cell Regen(Lond),4,2. FRANCOIS,M.,CAPRINI,A.,HOSKING,B.,ORSENIGO,F.,WILHELM,D.,BROWNE,C.,PAAVONEN,K.,KARNEZIS,T.,SHAYAN,R.,DOWNES,M.,et al.2008.Sox18 induces development of the lymphatic vasculature in mice.Nature,456,643-7. FUKADA,H.,STURTEVANT,J.M.& QUIOCHO,F.A.1983.Thermodynamics of the binding of L-arabinose and of D-galactose to the L-arabinose-binding protein of Escherichia coli.J Biol Chem,258,13193-8. GAGOSKI,D.,MUREEV,S.,GILES,N.,JOHNSTON,W.,DAHMER-HEATH,M.,SKALAMERA,D.,GONDA,T.J.& ALEXANDROV,K.2015.Gateway-compatible vectors forHigh-throughput protein expression in pro- and eukaryotic cell-free systems.J Biotechnol,195,1-7. GAMPER,A.M.& ROEDER,R.G.2008.Multivalent Binding of p53 to the STAGA Complex Mediates Coactivator Recruitment after UV Damage.Molecular and Cellular Biology,28,2517-2527. GUBBAY,J.,COLLIGNON,J.,KOOPMAN,P.,CAPEL,B.,ECONOMOU,A.,MUNSTERBERG,A.,VIVIAN,N.,GOODFELLOW,P.& LOVELL-BADGE,R.1990.A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes.Nature,346,245-50. HOPKINS,A.L.& GROOM,C.R.2002.The druggable genome.Nat Rev Drug Discov,1,727-30. HOSKING,B.M.,WANG,S.C.,CHEN,S.L.,PENNING,S.,KOOPMAN,P.& MUSCAT,G.E.2001.SOX18 directly interacts with MEF2C in endothelial cells.Biochem Biophys Res Commun,287,493-500. HOSKING,B.M.,WANG,S.C.,DOWNES,M.,KOOPMAN,P.& MUSCAT,G.E.2004.The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sry-relatedHigh mobility group box gene,Sox18.J Biol Chem,279,5314-22. HUANG,Y.H.,JANKOWSKI,A.,CHEAH,K.S.,PRABHAKAR,S.& JAUCH,R.2015.SOXE transcription factors form selective dimers on non-compact DNA motifs through multifaceted interactions between dimerization andHigh-mobility group domains.Sci Rep,5,10398. IRWIN,J.J.,DUAN,D.,TOROSYAN,H.,DOAK,A.K.,ZIEBART,K.T.,STERLING,T.,TUMANIAN,G.& SHOICHET,B.K.2015.An Aggregation Advisor for Ligand Discovery.Journal of Medicinal Chemistry,58,7076-7087. KLAUS,M.,PROKOPH,N.,GIRBIG,M.,WANG,X.,HUANG,Y.H.,SRIVASTAVA,Y.,HOU,L.,NARASIMHAN,K.,KOLATKAR,P.R.,FRANCOIS,M.,et al.2016.Structure and decoy-mediated inhibition of the SOX18 / Prox1-DNA interaction.Nucleic Acids Res,44,3922-35. KOVTUN,O.,MUREEV,S.,JUNG,W.,KUBALA,M.H.,JOHNSTON,W.& ALEXANDROV,K.2011.Leishmania cell-free protein expression system.Methods,55,58-64. LAGORCE,D.,SPERANDIO,O.,GALONS,H.,MITEVA,M.A.& VILLOUTREIX,B.O.2008.FAF-Drugs2:free ADME / tox filtering tool to assist drug discovery and chemical biology projects.BMC Bioinformatics,9,396. LAX,I.,JOHNSON,A.,HOWK,R.,SAP,J.,BELLOT,F.,WINKLER,M.,ULLRICH,A.,VENNSTROM,B.,SCHLESSINGER,J.& GIVOL,D.1988.Chicken epidermal growth factor(EGF)receptor:cDNA cloning,expression in mouse cells,and differential binding of EGF and transforming growth factor alpha.Mol Cell Biol,8,1970-8. LEUNG,C.-H.,CHAN,D.S.-H.,MA,V.P.-Y.& MA,D.-L.2013.DNA-Binding Small Molecules as Inhibitors of Transcription Factors.Medicinal Research Reviews,33,823-846. LIU,L.J.,LEUNG,K.H.,CHAN,D.S.,WANG,Y.T.,MA,D.L.& LEUNG,C.H.2014.Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening.Cell Death Dis,5,e1293. LOPEZ-BIGAS,N.,BLENCOWE,B.J.& OUZOUNIS,C.A.2006.Highly consistent patterns for inheritedHuman diseases at the molecular level.Bioinformatics,22,269-77. MAPP,A.K.,PRICER,R.& STURLIS,S.2015.Targeting transcription is no longer a quixotic quest.Nat Chem Biol,11,891-894. MCMILLIAN,M.K.,LI,L.,PARKER,J.B.,PATEL,L.,ZHONG,Z.,GUNNETT,J.W.,POWERS,W.J.& JOHNSON,M.D.2002.An improved resazurin-based cytotoxicity assay forHepatic cells.Cell Biol Toxicol,18,157-73. MIAN,I.S.,BRADWELL,A.R.& OLSON,A.J.1991.Structure,function and properties of antibody binding sites.Journal of Molecular Biology,217,133-151. MITTAL,D.,YOUNG,A.,STANNARD,K.,YONG,M.,TENG,M.W.,ALLARD,B.,STAGG,J.& SMYTH,M.J.2014.Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.Cancer Res,74,3652-8. MIYOSHI,K.,TAKAISHI,M.,NAKAJIMA,K.,IKEDA,M.,KANDA,T.,TARUTANI,M.,IIYAMA,T.,ASAO,N.,DIGIOVANNI,J.& SANO,S.2011.Stat3 as a therapeutic target for the treatment of psoriasis:a clinical feasibility study with STA-21,a Stat3 inhibitor.J Invest Dermatol,131,108-17. MUREEV,S.,KOVTUN,O.,NGUYEN,U.T.& ALEXANDROV,K.2009.Species-independent translational leaders facilitate cell-free expression.Nat Biotechnol,27,747-52. NARASIMHAN,K.,MICOINE,K.,LACOTE,E.,THORIMBERT,S.,CHEUNG,E.,HASENKNOPF,B.& JAUCH,R.2014.Exploring the utility of organo-polyoxometalateHybrids to inhibit SOX transcription factors.Cell Regen(Lond),3,10. NARASIMHAN,K.,PILLAY,S.,BIN AHMAD,N.R.,BIKADI,Z.,HAZAI,E.,YAN,L.,KOLATKAR,P.R.,PERVUSHIN,K.& JAUCH,R.2011.Identification of a polyoxometalate inhibitor of the DNA binding activity of Sox2.ACS Chem Biol,6,573-81. NG,C.K.,LI,N.X.,CHEE,S.,PRABHAKAR,S.,KOLATKAR,P.R.& JAUCH,R.2012.Deciphering the Sox-Oct partner code by quantitative cooperativity measurements.Nucleic Acids Res,40,4933-41. NIWA,H.,OGAWA,K.,SHIMOSATO,D.& ADACHI,K.2009.A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells.Nature,460,118-122. PENNISI,D.,GARDNER,J.,CHAMBERS,D.,HOSKING,B.,PETERS,J.,MUSCAT,G.,ABBOTT,C.& KOOPMAN,P.2000.Mutations in Sox18 underlie cardiovascular andHair follicle defects in ragged mice.Nat Genet,24,434-7. PERISSI,V.& ROSENFELD,M.G.2005.Controlling nuclear receptors:the circular logic of cofactor cycles.Nat Rev Mol Cell Biol,6,542-54. PILLINGER,M.H.,CAPODICI,C.,ROSENTHAL,P.,KHETERPAL,N.,HANFT,S.,PHILIPS,M.R.& WEISSMANN,G.1998.Modes of action of aspirin-like drugs:Salicylates inhibit Erk activation and integrin-dependent neutrophil adhesion.Proceedings of the National Academy of Sciences,95,14540-14545. PROKOP,J.W.,LEEPER,T.C.,DUAN,Z.H.& MILSTED,A.2012.Amino acid function and docking site prediction through combining disease variants,structure alignments,sequence alignments,and molecular dynamics:a study of theHMG domain.BMC Bioinformatics,13 Suppl 2,S3. REICHMANN,D.,RAHAT,O.,ALBECK,S.,MEGED,R.,DYM,O.& SCHREIBER,G.2005.The modular architecture of protein-protein binding interfaces.Proc Natl Acad Sci U S A,102,57-62. SACILOTTO,N.,MONTEIRO,R.,FRITZSCHE,M.,BECKER,P.W.,SANCHEZ-DEL-CAMPO,L.,LIU,K.,PINHEIRO,P.,RATNAYAKA,I.,DAVIES,B.,GODING,C.R.,et al.2013.Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development.Proc Natl Acad Sci U S A,110,11893-8. SARKAR,A.&HOCHEDLINGER,K.2013.The Sox Family of Transcription Factors:Versatile Regulators of Stem and Progenitor Cell Fate.Cell Stem Cell,12,15-30. SENISTERRA,G.,CHAU,I.& VEDADI,M.2012.Thermal denaturation assays in chemical biology.Assay Drug Dev Technol,10,128-36. SENISTERRA,G.A.& FINERTY,P.J.,JR.2009.High throughput methods of assessing protein stability and aggregation.Mol Biosyst,5,217-23. SENISTERRA,G.A.,MARKIN,E.,YAMAZAKI,K.,HUI,R.,VEDADI,M.& AWREY,D.E.2006.Screening for ligands using a generic andHigh-throughput light-scattering-based assay.J Biomol Screen,11,940-8. SENISTERRA,G.A.,SOOHONG,B.,PARK,H.W.& VEDADI,M.2008.Application ofHigh-throughput isothermal denaturation to assess protein stability and screen for ligands.J Biomol Screen,13,337-42. SHRAKE,A.& ROSS,P.D.1990.Ligand-induced biphasic protein denaturation.J Biol Chem,265,5055-9. SHRAKE,A.& ROSS,P.D.1992.Origins and consequences of ligand-induced multiphasic thermal protein denaturation.Biopolymers,32,925-40. SIERECKI,E.,GILES,N.,POLINKOVSKY,M.,MOUSTAQIL,M.,ALEXANDROV,K.& GAMBIN,Y. SIERECKI,E.,STEVERS,LM,GILES,N.,POLINKOVSKY,ME,MOUSTAQIL,M.,MUREEV,S.,JOHNSTON,WA,DAHMER-HEATH,M.,SKALAMERA,D.,GONDA,TJ,et al AlphaScreen and single-molecule spectroscopy.Mol Cell Proteomics,13,2233-45. VAQUERIZAS,JM,KUMMERFELD,SK,TEICHMANN,SA& LUSCOMBE,NM2009.A census ofHuman transcription factors:function,expression and evolution.Nat Rev Genet,10,252-63. VASSILEV, LT, VU, BT, GRAVES, B., CARVAJAL, D., PODLASKI, F., FILIPOVIC, Z., KONG, N., KAMMLOTT, U., LUKACS, C., KLEIN, C., et al MDM2.Science,303,844-8. VOGLER,M.,DINSDALE,D.,DYER,M.J.& COHEN,G.M.2009.Bcl-2 inhibitors:small molecules with a big impact on cancer therapy.Cell Death Differ,16,360-7. WRIGHT,P.E.& DYSON,H.J.2015.Intrinsically disordered proteins in cellular signalling and regulation.Nat Rev Mol Cell Biol,16,18-29. ZHANG,J.H.,CHUNG,T.D.& OLDENBURG,K.R.1999.A Simple Statistical Parameter for Use in Evaluation and Validation ofHigh Throughput Screening Assays.J Biomol Screen,4,67-73. DRAGO,R.L.C.A.R.,Thermodynamic Data for the Formation of Molecular Complexes between PhenylSubstituted Amides and Iodine.J.Am.Chem.Soc,1963.85(5):p.505-508 S.O.DE SILVA,J.N.R.,R.J.BILLEDEAU,X.WANG,D.J.NORRIS,AND V.SNIECKUS,Directed orfho metalation of n,n-diethyl benzamides.methodology and regiospecific synthesis of useful contiguously tri- and tetra- substituted oxygenated aromatics,phthalides and phthalic anhydrides.Tetrahedro,1992.48(23):p.4863-4878. ZIMMERMANN,T.J.,et al.,Discovery of a potent and selective inhibitor forHuman carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.Bioorganic & Medicinal Chemistry,2009.17(2):p.530-536. JO,G.,et al.,Complete NMR data of methoxylated cis- and trans-stilbenes as well as 1,2-diphenylethanes.Magnetic Resonance in Chemistry,2011.49(6):p.374-377. TAUB,D.,GIROTRA,N,N.,HOFFSOMMER,R.D.,KUO,C.H.,SLATES,H.L.,WEBER,S.,.L.WENDLER,Total synthesis of the macrolide,zearalenone.Tetrahedron,1968.24:p.2443-2461. SUBHASH P.KHANAPURE,R.T.R.,AND EDWARD R.BIEHL,The preparation of anthraquinones and anthracyclinones via the reaction ofHaloarenes and cyanophthalides under aryne-forming Conditions.J.Org.Chem.,1987.52:p.5685-5690. MAL,D.,et al.,DBU-CH3I,a Potential Substitute for CH2N2 in the preparation of methyl esters and methyl aryl ethers:Studies with assorted acids.Synthetic Communications,2008.38(22):p.3937-3946.

[0179] Example 2 Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice material and method Experimental reproducibility All data and statistical analyses in this study were generated from at least three independent experiments unless otherwise indicated. Technical replicates were included in each experiment to reduce background noise and detect technical anomalies. The samples of the different experimental conditions were not subjected to any particular method of randomization and the groups were evaluated under open-label conditions.

[0180] Plasmid preparation for cell-free expression The genetically encoded tags used herein are enhanced GFP (GFP), mCherry (Cherry) and cMyc (myc). The proteins were cloned into the following cell-free expression Gateway destination vectors, respectively: N-terminal GFP tagged (pCellFree_G03), N-terminal Cherry-cMyc (pCellFree_G07) and C-terminally Cherry-cMyc tagged (pCellFree_G08) (Gagoski et al., 2015). Open reading frames (ORFs) corresponding to human SOX7 (BC071947), SOX17, RBPJ (BC020780) and MEF2C (BC026341) were sourced from the human ORFeome collection versions 1.1 and 5.1 or the human Orfeome collaboration OCAA collection (Open Biosystems) and cloned at the UQ Diamantina Institute, an ARVEC facility, as previously described. The entry clone pDONOR223 or pENTR201 vector was exchanged for the ccdB gene in the expression plasmid by LR recombination (Life Technologies, Australia). The full-length human SOX18 gene was synthesized (IDT) and transfer into the vector was achieved using Gateway PCR cloning.

[0181] Cell-free protein expression Translation competent Leishmania tarentolae extract (LTE) was prepared as previously described ( Mureev et al., 2009 ; Kovtun et al., 2011 ). 30 nM GFP template plasmid and 60 nM Cherry template plasmid were added to the LTE and incubated at 27° C. for 3 hours to allow co-expression of the protein pairs.

[0182] ALPHA-Screen assay The ALPHA-Screen assay was performed using a cMyc detection kit and Proxiplate-384 Plus plates (PerkinElmer) as previously described ( Sierecki et al., 2014 ). Serial dilutions of each sample were measured. LTE lysates co-expressing the protein of interest were diluted in buffer A (25 mM HEPES, 50 mM NaCl). For the assay, 12.5 μL (0.4 μg) of anti-cMyc coated acceptor beads in Buffer B (25 mM HEPES, 50 mM NaCl, 0.001% NP40, 0.001% casein) was aliquoted into each well. Then, 2 μL of diluted sample and 2 μL of biotin-labeled GFP-Nanotrap in buffer A were added. The plates were incubated at room temperature for 45 minutes. Then, 2 μL (0.4 μg) of streptavidin-coated donor beads, diluted in buffer A, were added, followed by incubation for 45 minutes at room temperature in the dark. ALPHA-Screen signals were obtained on an Envision Multilabel Plate Reader (PerkinElmer) using the manufacturer's recommended settings (excitation: 680 / 30 nm for 0.18 seconds, emission: 570 / 100 nm after 37 ms). The resulting bell-shaped curve indicates a positive interaction, while a flat line reflects a lack of interaction between the proteins. Each protein pair was repeated a minimum of three times using separate plates. The binding index was calculated as follows: BI=[(I-I_neg) / (I_ref-I_neg)]×100

[0183] For each experiment, I is the maximum signal level (top of the Hook effect curve) and Ineg is the minimum (background) signal level. Signals were normalized to the Iref signal obtained for the interaction of SOX18 with itself.

[0184] For the PPI disruption assay, protein pairs expressed in LTE were incubated for 1 hour with 100 μM Sm4 or DMSO alone (0.7% DMSO final). In addition, 100 μM Sm4 or DMSO was added to buffer B. PPI disruption was calculated as follows: (1-I_Sm4 / I_DMSO) × 100.

[0185] I C 50 For the determination, the assay was identical but a dilution range of Sm4 was used (0.3-300 μM). The percentage of interaction was calculated as follows: I_Sm4 / I_DMSO × 100. Data from at least three independent experiments were fitted using 3-parameter nonlinear regression in GraphPad Prism (RRID:SCR_007370) version 6.0.

[0186] Cell culture and transfection COS-7 cells were purchased from ATCC (CRL-1651, RRID:CVCL_0224) and cultured at 37°C, 5% CO2 in DMEM (Life technologies, 11995) supplemented with FBS, sodium pyruvate, L-glutamine, penicillin, streptomycin, non-essential amino acids and HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid). COS-7 cells were transfected for 4-6 hours and incubated for an additional 24 hours before lysis and luciferase assay (Perkin Elmer, 6016711). Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza Australia (CC-2519A). For ChIP-MS, ChIP-seq and RNA-seq analyses, HUVECs were transfected for 7 h and incubated for an additional 14 h. During small molecule treatment, cells were grown in medium containing low serum (0.4% FBS). HUVECs were cultured in supplemented EGM-2 medium at 37° C., 5% CO 2 according to the EGM-2 bullet kit instructions (Lonza, CC-3162). Cells were grown in 35 mm dishes to 80-90% confluency and transfected with plasmid mouse pSG5 Sox18, plasmid pSG5 cMyc-Sox18, or plasmid cMyc using X-tremegene 9 DNA transfection reagent (Roche, 06365787001) according to the manufacturer's instructions. All cell lines were negative for mycoplasma contamination.

[0187] Chromatin immunoprecipitation ChIP experiments were performed as previously described ( Schmidt et al., 2009 ). For HUVECs overexpressing cMyc-tagged SOX18, immunoprecipitation was performed using anti-cMyc (Cell Signaling, #2276, RRID:AB_2314825).

[0188] ChIP-seq and analysis After IP, DNA amplification was performed using the TruSeq ChIPseq kit (Illumina, IP-202-1012) with 0.5 μM universal reverse and forward PCR primers containing the index sequence of choice in 50 μL of 1× NEBNext High-Fidelity PCR Master Mix (New England Biolabs, M0541). The number of PCR cycles ranged from 13 to 18, depending on the ChIP efficiency. The PCR product was purified using AMPure beads (1.8 volumes) and eluted in 20 μL of resuspension buffer (Tris acetate 10 mM, pH 8). Libraries were quantified using the KAPA Library Quantification Kit for Illumina Sequencing Platform (KAPA Biosystems, KK4824) and 50 bp single-end reads were sequenced on a HiSeq2500 according to the manufacturer's protocol. Illumina fastq files were mapped to the GRCh37 / UCSC hg19 genome assembly using bowtie and peaks were requested using the inputs using MACS version 2.1.0. To avoid false positive peak claims due to the cMyc epitope, ChIP-seq with only the cMyc epitope was performed in parallel with SOX18-cMyc ChIP-seq, and peaks claimed in these experimental conditions were subtracted to those claimed in the SOX18-cMyc condition. The functional significance of cis-regulatory regions was analyzed using the Genomic Regions Enrichment of Annotations Tool (GREAT, RRID:SCR_005807). ChIP-seq data are available in the ArrayExpress database (www.ebi.ac.uk / arrayexpress, RRID: SCR_002964) under accession numbers E-MTAB-4480 (SOX7) and E-MTAB-4481 (SOX18).

[0189] ChIP-MS (RIME) ChIP-MS experiments were performed as previously described ( Mohammed et al., 2013 ). Peptides common to SOX18-cMyc and the negative control (cMyc only) were discarded, and only peptides uniquely detected in SOX18-cMyc transfected cells were considered for analysis.

[0190] RNA-seq and analysis Quadruplicate samples were processed for whole transcriptome sequencing using the TruSeq stranded total RNA library prep kit (Illumina). Reads were mapped to the hg19 reference human genome using the STAR aligner (Dobin et al., 2013) and only uniquely aligned reads were considered. Transcripts were assigned to genes using htseq_count (HTseq package) (Anders, Pyl, & Huber, 2015) and differential expression was calculated using DEseq2 (Love, Huber, & Anders, 2014). Genes with an adjusted p-value <0.05 were considered significant.

[0191] Differentially expressed genes were identified in SOX18-overexpressing cells between Sm4 treatment and DMSO controls and segregated into up-regulated and down-regulated (DOWN) genes. The locations of their transcription start sites (TSS) were correlated with the locations of available transcription factor binding events from the ENCODE consortium (RRID: SCR_006793) and from the SOX18 and SOX7 ChIP-seq experiments we performed in this study. To ensure TSS independence, a TSS was allowed to be assigned to only one ChIP-seq peak. Transcripts with an absolute fold change of 2 or more (log2FC ≥ 1 or ≤ -1) were included in the distance to TSS analysis. The median distance between the TSS and the binding event was compared to the expected distance of a set of randomly selected genes to obtain a median ratio. A control set of genes was selected from the pool of genes expressed in HUVEC such that they had a similar distribution of expression levels. To ensure that no bias was introduced by potential co-regulation of genes by SOX18 and any other transcription factors analyzed, we subtracted genes with SOX18 peaks from the analysis of other transcription factors. A reverse analysis was also performed, subtracting genes containing c-JUN peaks from the analysis of SOX18. RNA-seq data are available in the ArrayExpress database (www.ebi.ac.uk / arrayexpress) under accession number E-MTAB-4511.

[0192] Quantitative RT-PCR Total RNA was extracted using the RNeasy mini kit (Qiagen, 74106) according to the manufacturer's protocol, including on-column DNA digestion. cDNA was synthesized from 1 μg of purified RNA using the High Performance cDNA Reverse Transcription Kit (Life Technologies, 4368813). Amplification and quantification of target cDNA was performed in technical triplicates of at least three biological replicates using the SYBR Green (Life Technologies, 4312704) method. Reactions were carried out in 384-well plates at 10 μL using a ViiA 7 Real-Time PCR system. Housekeeper genes (β-actin for tg(Dll4in3:eGFP), ef1α for tg(-6.5kdrl:eGFP), chd5 for tg(fli1a:eGFP,-6.5kdrl:mCherry), RPL13 and GAPDH for HUVEC) were selected based on the stability of their expression across the set of experimental conditions or based on their vascular expression and normalized to endothelial cell content. Primer efficiencies were calculated using LinRegPCR and amplification data were analyzed using ViiA7 software and Q-gene PCR analysis template.

[0193] Zebrafish aquaculture and analysis Zebrafish were maintained as previously described (Hogan et al., 2009) and all procedures involving animals complied with the guidelines of the Animal Ethics Committee of the University of Queensland (IMB / 030 / 16 / NHMRC / ARC / HF) or were approved by local ethical assessment and licensed by the UK Home Office (PPL 30 / 2783 and PPL 30 / 3324). tg(-6.5kdrl:eGFP), tg(fli1a:eGFP, -6.5kdrl:mCherry) and tg(Dll4in3:GFP) was described previously ( Sacilotto et al., 2013 ; Duong et al., 2014 ; Lawson and Weinstein, 2002 ).

[0194] Dechorionation was performed by treatment with 25 μg / mL or 5 μg / mL pronase for 2 hours or overnight, respectively. Zebrafish larvae were anesthetized with 0.01% tricaine. Representative larvae were embedded in 0.5% low melting point agarose and imaged using a Zeiss LSM 710 confocal microscope.

[0195] Zebrafish in situ hybridization and section analysis Whole-mount in situ hybridization of zebrafish (28 and 48 hpf) was performed as previously described ( Thisse and Thisse, 2008 ) using probe templates for dab ( Song et al., 2004 ) and ephrinB2a ( Durbin et al., 1998 ). The Yolk sac was removed before the addition of 70% glycerol. For transverse sections, whole larvae embedded in 4% agarose were sectioned at 150 μm using a Leica VT1000 S vibrating microtome. Imaging was performed on an Olympus BX-51 brightfield microscope (ISH), and a Zeiss LSM 510 confocal microscope. For fluorescence imaging, larvae were stained with DAPI before embedding.

[0196] Small molecule treatment and morpholino injections All treatments with putative small molecule inhibitors, as well as corresponding control conditions, were performed in the presence of low concentrations of DMSO (≦1% v / v) to obtain reliable homogenous solutions and were prepared from 10 mM DMSO stocks. For cell culture, small molecules were added directly to fresh medium after transfection and cells were grown in this medium until the time of cell harvest. For in vivo experiments involving zebrafish, compound treatment was initiated at the indicated time points by replacing the medium, and medium + compound was refreshed daily for the duration of the experiment. Where necessary, PTU treatment (0.003%) was performed in parallel with the small molecules to block pigment formation. Previously published and validated morpholino oligomers against sox7, sox18 (Herpers et al., 2008) and rbpj (Sacilotto et al., 2013) were microinjected into single-cell zebrafish zygotes at suboptimal concentrations of 5 ng for experiments performed with tg(6.5kdrl:eGFP) and tg(fli1a:eGFP,-6.5kdrl:mCherry) and 0.125–0.15 pmol for experiments performed with tg(Dll4in3:eGFP).

[0197] Mice and Mouse Models BALB / c wild type (WT) mice were purchased from the Walter and Eliza Hall Institute for Medical Research and were used between 6 and 10 weeks of age. Mouse 4T1.2 breast cancer cells were cultured in complete RPMI with 10% FBS in a 5% CO2 incubator. 5×10 4 4T1.2 tumor cells were inoculated into the fourth mammary fat pad of BALB / c WT mice as previously described ( Mittal et al., 2014 ). Briefly, 3 days after tumor implantation, mice were orally gavaged with 25 mg / kg body weight Sm4, aspirin or vehicle PBS daily for 10 days. Tumor size was measured as the product of two perpendicular diameters using digital calipers. Plasma was collected from mice on days 7 and 12 and analyzed for Sm4 concentration using a 4000 Qtrap LC-MS / MS system mass spectrometer. On day 12, mice were anesthetized and either the primary tumor was surgically removed or the mice underwent the surgical procedure without the primary tumor resection, and the wound was closed with surgical clips. Tumors were collected in formalin for histological examination. Lungs were harvested on day 28 and fixed in Bouin's fixative for 24 hours, and metastatic tumor nodules were counted under a dissection microscope. Mice were monitored for survival in experiments in which lungs were not harvested. Groups of 6–14 mice per experiment were used in experimental tumor assays to ensure sufficient power for detection of biological differences. All experiments were approved by the QIMR Berghofer Medical Research Institute Animal Ethics Committee (P1505).

[0198] For quantification of vasculature in tumors, fixed tissues were embedded in 4% agarose and whole sectioned at 300 μm on a Leica VT1000 S vibrating microtome. Sections were collected onto glass slides and imaged for bright field analysis of perfused vascular penetration. Subsequently, immunofluorescence staining on sections was performed using anti-mouse endomucin (cat# sc-53941, RRID:AB_2100038), ERG (cat# ab92513, RRID:AB_2630401), PROX1 (AngioBio cat#11-002, RRID:AB_10013720) and podoplanin (AngioBio cat#11-033, AB_2631191) antibodies. The entire tumor section was imaged by acquiring a series of images along the z-axis using a 10× objective on a Zeiss LSM 710 confocal microscope. Subsequently, high-resolution images of 3-4 separate areas from each tumor were taken using a 20× objective to account for heterogeneity in vascular density within the tumor and minimize bias. Raw image files of identical dimensions (1274.87 μm × 1274.87 μm × 89.05 μm) were loaded into Imaris (Bitplane, RRID: SCR_007370) and the “spots” function was used to count ERG or PROX1 positive nuclei and “surface” to calculate the volume or area of ​​endomucin or podoplanin positive vessels. For each tumor (n=6), counts from multiple fields were averaged and data were plotted in Graphpad Prism 6.

[0199] BALB / c wild-type (WT) mice were purchased from the Walter and Eliza Hall Institute for Medical Research and used at 6–10 weeks of age. Mouse 4T1.2 breast cancer cells were cultured in complete RPMI with 10% FBS in a 5% CO2 incubator. 5×10 4 4T1.2 tumor cells were inoculated into the fourth mammary fat pad of BALB / c WT mice as previously described ( Mittal et al., 2014 ). Briefly, on day 3 after tumor implantation, mice were orally gavaged with different doses of Sm4 ranging from 5 mg / kg to 50 mg / kg body weight, or vehicle PBS daily for 10 days. Tumor size was measured as the product of two perpendicular diameters using digital calipers. On day 12, mice were anesthetized, the primary tumor was surgically removed, and the wound was closed with surgical clips. Tumors were harvested in formalin for histological examination. Mouse survival was monitored in groups of 6-12 mice per experiment to ensure adequate power for the detection of biological differences. All experiments were approved by the QIMR Berghofer Medical Research Institute Animal Ethics Committee (P1505).

[0200] Results and Discussion Although SOX proteins activate individual target genes by recruiting specific interaction partners ( Sarkar and Hochedlinger, 2013 ), only two protein-protein interactions involving the SOXF group (SOX18-MEF2C and SOX17-OCT4) have been identified to date ( Hosking et al., 2001 ; Jauch et al., 2011 ). We first mapped the SOX18 interactome (the network of SOX18 interacting partners) using a combination of unbiased proteomic techniques. Chromatin immunoprecipitation coupled to mass spectrometry (ChIP-MS) provided a first-pass screen of proteins associated with chromatin-bound SOX18 in human umbilical vein endothelial cells (HUVECs) ( Mohammed et al., 2013 ), and then ALPHA-Screen converted SOX18-dependent complexes into pairwise interactions using in vitro translated full-length proteins ( Figure 9A ) ( Mureev et al., 2009 , Kovtun et al., 2011 , Sierecki et al., 2013 , Sierecki et al., 2014 , Gambin et al., 2014 ). ChIP-MS analysis revealed 289 proteins, representing diverse gene ontology (GO) classes of molecular functions directly or indirectly related to SOX18 ( Figures 9B and 10A-C ). To increase our chances of identifying direct interactors, we focused on proteins known to be nucleic acid and / or protein binding (Figure 9B, purple). From this subset, we selected eight known transcription factors, helicases, corepressors, RNA-binding and DNA repair molecules (Fig. 10A,B). Using the ALPHA-Screen, we observed that SOX18 interacted with itself and also formed pairwise interactions with DDX1, DDX17, ILF3, STAT1, TRIM28 and XRCC5 (Figure 9C, left column "+", and Figure 10D).

[0201] In addition, the inventors studied potential pairwise interactions of six well-known TFs that can regulate endothelial cell function (ESR1, NR2F2, RBPJ, SOX7, SOX17 and CTNNB1) and identified only the SOX18 protein partner MEF2C (Hosking et al., 2001). The well-characterized SOX9 homodimer ( Bernard et al., 2003 ) was included as a positive control to validate the ALPHA-Screen signal ( FIG. 10D ). SOX18 was found to interact with all endothelial transcription factors tested, with the possible exception of SOX17 and CTNNB1, which exhibited binding affinities below an arbitrary threshold (FIG. 9C, "-").

[0202] Having identified a variety of proteins that can interact with SOX18, we then proceeded to test the activity of a small molecule compound, Sm4 (FIG. 10E), against these interactions. Sm4, derived from a natural product found in the brown alga Caulocystis cephalornithos, was identified in a high-throughput screen for potential SOX18 blockers (see Example 1). We found that Sm4 significantly disrupted 6 of 12 SOX18 interactions examined (Figure 9C, right column), indicating that IC 50 Values ​​ranged from 3.3 μM for SOX18-SOX18 to 65.9 μM for the SOX18-RBPJ dimer ( Figures 9 D and 10 F). To assess the differential effects of Sm4 on different SOXF members, we explored an additional set of PPIs between all three SOXF proteins and MEF2C, RBPJ and OCT4 (FIG. 11). Like SOX18, SOX7 can interact with RBPJ and with SOX18 itself, both interactions being at least partially disrupted by Sm4. We further found that all three SOXF proteins can form heterodimers with OCT4, but only the SOX17-OCT4 interaction is affected by Sm4. Importantly, neither SOX7 nor SOX17 have the ability to form homodimers, and therefore, this component of the Sm4 mode of action is highly specific for the SOX18-SOX18 interaction. Further demonstrating this, SOX9 homodimerization was unaffected by Sm4 up to 200 μM (Unperturbed) (Figures 9C-D and 10D). These results indicate that the selectivity of Sm4 is biased towards a subset of SOX18-associated PPIs, but has the ability to interfere with the recruitment of SOX7 or SOX17 protein partners. This feature of Sm4 may have an advantage in blocking the SOXF redundancy mechanism ( Hosking et al., 2009 ; Kim et al., 2016 ).

[0203] To assess how SOX18 PPI disruption translates into transcriptional dysregulation, we next performed a combined genome-wide RNA-seq and ChIP-seq analysis in HUVECs. The most common binding motif identified from SOX18 ChIP-seq peaks corresponded to the previously reported SOX motif 5'-AACAAT-3' (Figure S4A), and the validity of this ChIP-seq dataset was further confirmed by GO term analysis and identification of known SOX18 target genes, such as Prox1 and Vcam1 (Figure S4B) (Francois et al., 2008; Hosking et al., 2004). We compared the global transcriptional effects of Sm4 treatment versus DMSO control in SOX18-overexpressing cells (Figure S13C-E) and overlaid this list of differentially expressed genes onto the SOX18 ChIP-seq dataset. Using this superposition, we calculated the distance between the transcription start site (TSS) of a gene and the TF binding event as a proxy for the likelihood of direct transcriptional regulation. To enable analysis of how this distance is altered by Sm4, we established a reference distance between the TSS and SOX18 binding events of a random gene set (Figure 12A). In parallel, we performed the same analysis for SOX7 (generated in-house) and all seven transcriptional regulators available from the ENCODE consortium (GATA2, c-FOS, c-JUN, CTCF, EZH2, MAX, c-MYC). Thereby, we were able to distinguish between transcription targeting SOX18 and potential off-target effects of other endothelial-specific transcription factors.

[0204] Cumulative SOX18 peak-to-TSS distances showed that, overall, SOX18 peaks were 3.6 times closer (p-value < 0.001) to the TSSs of Sm4-downregulated genes than to randomly distributed TSSs (Figure 12B, top left). These results are an indirect indication that Sm4-affected genes are dysregulated through a specific effect on SOX18 transcriptional activity. This correlation was not observed with seven other transcription factors tested (Figures 12B and 13F), indicating that Sm4 has no off-target effects on these TF activity. Interestingly, the TSSs of Sm4-downregulated genes were 2.05-fold closer to c-JUN binding events (p-value=0.011, Appendix 1c). Although only mildly significant, this may suggest possible co-regulation by SOX18 and c-JUN for this subset of Sm4-downregulated genes. Indeed, analysis of known motifs in SOX18 ChIP-seq peaks revealed an over-representation of c-JUN binding motifs (3.23% of SOX18 peaks, p-value=1e-302), and ALPHA-Screen analysis further established that SOX18 and c-JUN can physically interact (Figure 14). We found that the expression levels of other TFs tested were not altered by Sm4 treatment. This is an important observation because it indicates that no bias is introduced due to off-target regulation of transcript levels for these transcription factors in the presence of Sm4.

[0205] To address the issue of potential transcriptional off-target effects of Sm4 on SOX TF family members, we focused on the closely related SOXF and SOXE proteins. Sm4 did not affect the transcriptional activity of either SOX17 or SOX9 proteins at any tested concentration (≦50 μM) in cell-based reporter assays ( Figure 15 ) ( Robinson et al., 2014 ; Lefebvre et al., 1997 ). Taken together, these results provide strong evidence for selective targeting of SOX18-mediated transcription compared with other key endothelial transcription factors and SOX proteins.

[0206] To study whether Sm4 can perturb Sox18 transcriptional activity in vivo, we used the tg(-6.5kdrl:eGFP) transgenic zebrafish reporter line, which has previously been validated as a readout for the combinatorial activity of Sox7 and Sox18 ( Duong et al., 2014 ). We treated these larvae at 20 hours post-fertilization (hpf) and observed that Sm4 treatment significantly reduced SOX18-dependent egfp transcript levels (61%), similar to the effect of combined sox7 / 18 depletion using morpholino oligonucleotides (MOs) (Figure 16A,B). Importantly, these zebrafish embryos developed normally and the inventors found no evidence of toxicity.

[0207] We then used a second transgenic zebrafish reporter line, tg(Dll4in3:eGFP), which harbors a regulatory element located in intron 3 of the dll4 gene. Although the activity of this Dll4in3 enhancer does not fully recapitulate endogenous dll4 expression (Wythe et al., 2013; Sacilotto et al., 2013) (Wythe et al., 2013 and Sacilotto et al., 2013), it does provide a useful tool to study the combinatorial activity of Sox7, Sox18 and the Notch effector Rbpj. Combinatorial genetic interference with sox7, sox18 and rbpj has been shown to abolish Dll4in3 activation, whereas single or double MO knockdown has a much milder effect ( Sacilotto et al., 2013 ). This mild repressive effect was reproduced by treatment with Sm4 alone (Fig. 16C, D). In addition, when a suboptimal dose of rbpj MO was combined with Sm4 treatment, the repression effect was significantly increased by 11.5% (Fig. S1C, D). These data indicate that Sm4 interferes with the coordinated activation of Sox7 / 18 and Rbpj at the Dll4in3 enhancer. As an in vivo negative control, we used a Sox9-dependent tg(col2a1:yfp) reporter line and observed that continuous Sm4 treatment between days 2 and 6 postfertilization did not perturb the transcriptional activity of Sox9 or the process of chondrogenesis (Figure S17). Taken together, this supports the proposed mechanism of action for Sm4 as a selective SOX18 inhibitor in vivo.

[0208] To further demonstrate small molecule inhibition of Sox18 function in vivo, we next investigated whether Sm4 treatment could produce a vascular phenotype similar to that of sox7 / sox18 genetically disrupted zebrafish (Hermkens et al., 2015), which is characterized by defective arteriovenous specification and reduced expression levels of arterial markers (Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008). We treated zebrafish larvae harboring the artery / vein reporter tg(fli1a:eGFP, -6.5kdrl:mCherry) with 1.5 μM Sm4 during relevant developmental times, starting at 16 hpf (Figure 18A). These larvae acquired an enlarged posterior cardinal vein (PCV) at the expense of the dorsal aorta (DA) (Figures 16E-G and 18B), had arteriovenous shunts and incomplete truncal circulation (Figures 18C,D). qRT-PCR analysis of vascular markers at 24 and 48 hpf revealed significant dysregulation of arterial and venous genes, especially efnb2a, hey1 and efnb4a, under Sm4-treated conditions compared to DMSO (Figures 16H and 18E).

[0209] Due to SoxF redundancy in arteriovenous specification, A / V dysplasia phenotypes are generally only observed in double loss of Sox7 and Sox18 function. Because Sm4 appears to partially disrupt Sox7-Rbpj and Sox7-Sox18 PPI in vitro, we focused on Sox7-specific phenotypes to evaluate whether this TF activity is inhibited by Sm4 in vivo. A hallmark of sox7 genetic disruption is a short circulation loop in the head formed by the dorsolateral artery (Mohammed et al., 2013), leading to perturbation of the facial circulation (Hermkens et al., 2015). In the presence of Sm4, we observed minor malformations to the LDA reminiscent of a partial Sox7 loss-of-function phenotype. However, blood circulation within the head was unaffected in Sm4-treated larvae, indicating that the short circulatory loop was not fully formed. This phenotype supports the conclusion that Sox7 activity is only partially affected in the presence of small compounds. Overall, these results are consistent with the genome-wide inhibitory effects observed in vitro and show that Sm4 selectively interferes with the transcriptional activity of Sox18 and SoxF-mediated angiogenesis in vivo.

[0210] As a final demonstration of the antiangiogenic potential of Sm4 in a therapeutically relevant setting, we next evaluated its efficacy in preclinical models of breast cancer. BALB / c mice were inoculated into the mammary fat pad with highly metastatic 4T1.2 breast cancer cells and tumors were allowed to engraft for 3 days after which treatment with either 25 mg / kg / day Sm4, aspirin, or the vehicle PBS was initiated (Figure 19A). Aspirin was chosen as a negative control due to its structural similarity to Sm4. Daily treatment was maintained for 10 days, after which the primary tumor was resected and the effect on disease latency was monitored (FIG. 19A). As an indirect indication of target engagement, we first confirmed the expression of Sox18 within the 4T1.2 tumor vasculature by in situ hybridization (FIG. 19B). We next proceeded to measure Sm4 bioavailability during the course of treatment. At two different time points, Sm4 was consistently detected in plasma, with mean concentrations increasing over time from 38.3 to 55.2 μg / mL (FIG. 19C).

[0211] PBS vehicle- or aspirin-treated mice succumbed to 4T1.2 tumor burden with median response times of 33 and 34 days, respectively (FIG. 19D). On the other hand, Sm4 treated mice showed a significant increase in overall survival with a median response time of 44 days (p value < 0.01). As shown in the Sm4 dose-response assessment in FIG. 20I, increasing concentrations of Sm4 led to further improvements in the overall survival of 4T1.2-inoculated mice. As an example, treatment of mice with 50 mg / kg Sm4 resulted in a median reaction time of 73 days, whereas vehicle-treated mice resulted in a median reaction time of 40 days.

[0212] Furthermore, to study what may cause such effects, tumor size and the formation of spontaneous lung metastases were monitored during treatment. Although the size of primary tumors was unchanged by Sm4 treatment (FIG. 19E), we found a 67% reduction in the mean number of lung metastases 28 days after tumor inoculation (FIG. 19F).

[0214] To establish a correlation between metastatic rate and the vascular response induced by the tumor, we studied the vascular density within the tumor and peritumoral areas (FIGS. 19G and 21). The entire tumor was dissected and bright field microscopy revealed a generalized decrease in vascular coverage, as indicated by the presence of red blood cells (FIG. 19G, star). Furthermore, analysis of endothelial cell markers ERG (nuclear) and endomucin (EMCN, membranous) using immunofluorescence staining showed a significant reduction in endothelial cell number (48%, p-value < 0.05) and vascular volume (55%, p-value < 0.01) in tumors from Sm4-treated mice (Figures 19H, I and 22). Using lymphatic-specific markers, PROX1 and podoplanin (PDPN), we also evaluated the effect of Sm4 on tumor-induced lymphangiogenic responses and found that the density of tumor associated lymphatic vessels and the number of lymphatic endothelial cells (70%, p-value < 0.001) were significantly reduced in the treated condition (65%, p-value < 0.01) (Figure 23). This lymphatic response to Sm4 treatment is consistent with loss of SOX18 function during lymphatic spread of solid cancers ( Duong et al., 2012 ). Taken together, this indicates that Sm4 improved the prognosis of induced breast cancer by interfering with tumor-induced angiogenesis and associated metastasis.

[0215] The induction of angiogenesis and lymphangiogenesis is a hallmark of solid tumors and a crucial step towards enabling tumor metastatic dissemination. Previous approaches to target transcription factors have focused on disrupting dysregulated oncogenes that promote tumor cell transformation ( Gormally, 2014 ; Illendula et al., 2015 ; Moellering et al., 2009 ; Zhang et al., 2012 ). Here we examine a novel complementary strategy that relies on targeting developmental transcription factors from the host vasculature, which can promote metastatic spread. Our results provide proof of concept that targeting the transcription factor SOX18 with Sm4 is an effective molecular strategy to disrupt metastatic spread in preclinical models of breast cancer.

[0216] Throughout this specification, the objective has been to describe preferred embodiments of the invention without limiting the invention to any one embodiment or collection of particular features. It will therefore be appreciated by those of skill in the art, in light of the instant disclosure, that various modifications and changes can be made to the particular embodiments exemplified without departing from the scope of the present invention.

[0217] All computer programs, algorithms, patent and scientific literature mentioned herein is incorporated by reference.

[0218] References Anders, S., PTPyl, and W. Huber. 2015. “HTSeq--a Python framework to work withHigh-throughput sequencing data.”Bioinformatics 31(2):166-9.doi:10.1093 / bioinformatics / btu638. Bernard, P., P. Tang, S. Liu, P. Dewing, VR Harley, and E. Vilain. 2003. “Dimerization of SOX9 is required for chondrogenesis, but not for sex determination.” Hum Mol Genet 12(14):1755-65. Cermenati,S.,S.Moleri,S.Cimbro,P.Corti,L.Del Giacco,R.Amodeo,E.Dejana,P.Koopman,F.Cotelli,and M.Beltrame.2008.“Sox18 and Sox7 play redundant roles in vascular development.”Blood 111(5):2657-66.doi:10.1182 / blood-2007-07-100412. Corada, M., F. Orsenigo, M.F.Morini, M.E.Pitulescu, G. Bhat, D. Nyqvist, F. Breviario, V. Conti, A. Briot, M.L.Iruela-Arispe, R.H.Adams, and E. Dejana. 2013. “Sox17 is indispensable for acquisition and maintenance of arterial identity.” Nat Commun 4:2609. doi:10.1038 / ncomms3609. Dobin,A.,CADavis,F.Schlesinger,J.Drenkow,C.Zaleski,S.Jha,P.Batut,M.Chaisson,and TRGingeras.2013.“STAR:ultrafast universal RNA-seq aligner.”Bioinformatics 29(1):15-21.doi:10.1093 / bioinformatics / bts635. Duong,T.,K.Koltowska,C.Pichol-Thievend,L.Le Guen,F.Fontaine,K.A.Smith,V.Truong,R.Skoczylas,S.A.Stacker,M.G.Achen,P.Koopman,B.M.Hogan,and M.Francois.2014.“VEGFD regulates blood vascular development by modulating SOX18 activity.”Blood 123(7):1102-12.doi:10.1182 / blood-2013-04-495432. Duong,T.,S.T.Proulx,P.Luciani,J.C.Leroux,M.Detmar,P.Koopman,and M.Francois.2012.“Genetic ablation of SOX18 function suppresses tumor lymphangiogenesis and metastasis of melanoma in mice.”Cancer Res 72(12):3105-14.doi:10.1158 / 0008-5472.CAN-11-4026. Durbin,L.,C.Brennan,K.Shiomi,J.Cooke,A.Barrios,S.Shanmugalingam,B.Guthrie,R.Lindberg,and N.Holder.1998.“Eph signaling is required for segmentation and differentiation of the somites.”Genes Dev 12(19):3096-109. Eom,B.W.,M.J.Jo,M.C.Kook,K.W.Ryu,I.J.Choi,B.H.Nam,Y.W.Kim,and J.H.Lee.2012.“The lymphangiogenic factor SOX 18:a key indicator to stage gastric tumor progression.”Int J Cancer 131(1):41-8.doi:10.1002 / ijc.26325. Francois,M.,A.Caprini,B.Hosking,F.Orsenigo,D.Wilhelm,C.Browne,K.Paavonen,T.Karnezis,R.Shayan,M.Downes,T.Davidson,D.Tutt,K.S.Cheah,S.A.Stacker,G.E.Muscat,M.G.Achen,E.Dejana,and P.Koopman.2008.“Sox18 induces development of the lymphatic vasculature in mice.”Nature 456(7222):643-7.doi:10.1038 / nature07391. Gagoski,Dejan,Sergey Mureev,Nichole Giles,Wayne Johnston,Mareike Dahmer-Heath,Dubravka Skalamera,Thomas J.Gonda,and Kirill Alexandrov.2015.“Gateway-compatible vectors forHigh-throughput protein expression in pro- and eukaryotic cell-free systems.”Journal of Biotechnology 195(0):1-7.doi:Http: / / dx.doi.org / 10.1016 / j.jbiotec.2014.12.006. Gambin,Y.,N.Ariotti,KAMcMahon,M.Bastiani,E.Sierecki,O.Kovtun,MEPolinkovsky,A.Magenau,W.Jung,S.Okano,Y.Zhou,N.Leneva,S.Mureev,W.Johnston,K.Gaus,JFHancock,BMCollins,KAlexandrov,and RGParton.2014.“Single-molecule analysis reveals self assembly and nanoscale segregation of two distinct cavin subcomplexes on caveolae.” Elife 3:e01434.doi:10.7554 / eLife.01434. Gormally, MV, TSDexheimer, G. Marsico, DASanders, C. Lowe, D. Matak-Vinkovic, S. Michael, A. Jadhav, G. Rai, DJMaloney, A. Simeonov, and S. Balasubramanian 5:5165.doi:10.1038 / ncomms6165. Hermkens, DM, A. van Impel, A. Urasaki, J. Bussmann, HJDuckers, and S. Schulte-Merker. Herpers,R.,E.van de Kamp,H.J.Duckers,and S.Schulte-Merker.2008.“Redundant roles for sox7 and sox18 in arteriovenous specification in zebrafish.”Circ Res 102(1):12-5.doi:10.1161 / CIRCRESAHA.107.166066. Hogan,B.M.,F.L.Bos,J.Bussmann,M.Witte,N.C.Chi,H.J.Duckers,and S.Schulte-Merker.2009.“Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting.”Nat Genet 41(4):396-8.doi:10.1038 / ng.321. Hosking,B.,M.Francois,D.Wilhelm,F.Orsenigo,A.Caprini,T.Svingen,D.Tutt,T.Davidson,C.Browne,E.Dejana,and P.Koopman.2009.“Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice.”Development 136(14):2385-91.doi:10.1242 / dev.034827. Hosking,B.M.,S.C.Wang,S.L.Chen,S.Penning,P.Koopman,and G.E.Muscat.2001.“SOX18 directly interacts with MEF2C in endothelial cells.”Biochem Biophys Res Commun 287(2):493-500.doi:10.1006 / bbrc.2001.5589. Hosking,B.M.,S.C.Wang,M.Downes,P.Koopman,and G.E.Muscat.2004.“The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sry-relatedHigh mobility group box gene,Sox18.”J Biol Chem 279(7):5314-22.doi:10.1074 / jbc.M308512200. Illendula,A.,J.A.Pulikkan,H.Zong,J.Grembecka,L.Xue,S.Sen,Y.Zhou,A.Boulton,A.Kuntimaddi,Y.Gao,R.A.Rajewski,M.L.Guzman,L.H.Castilla,and J.H.Bushweller.2015.“Chemical biology.A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice.”Science 347(6223):779-84.doi:10.1126 / science.aaa0314. Jauch,R.,I.Aksoy,A.P.Hutchins,C.K.Ng,X.F.Tian,J.Chen,P.Palasingam,P.Robson,L.W.Stanton,and P.R.Kolatkar.2011.“Conversion of Sox17 into a pluripotency reprogramming factor by reengineering its association with Oct4 on DNA.”Stem Cells 29(6):940-51.doi:10.1002 / stem.639. Jethon,A.,B.Pula,M.Olbromski,B.Werynska,B.Muszczynska-Bernhard,W.Witkiewicz,P.Dziegiel,and M.Podhorska-Okolow.2015.“Prognostic significance of SOX18 expression in non-small cell lung cancer.”Int J Oncol 46(1):123-32.doi:10.3892 / ijo.2014.2698. Kim,K.,I.K.Kim,J.M.Yang,E.Lee,B.I.Koh,S.Song,J.Park,S.Lee,C.Choi,J.W.Kim,Y.Kubota,G.Y.Koh,and I.Kim.2016.“SoxF Transcription Factors Are Positive Feedback Regulators of VEGF Signaling.”Circ Res 119(7):839-52.doi:10.1161 / CIRCRESAHA.116.308483. Kovtun,O.,S.Mureev,W.Jung,M.H.Kubala,W.Johnston,and K.Alexandrov.2011.“Leishmania cell-free protein expression system.”Methods 55(1):58-64.doi:10.1016 / j.ymeth.2011.06.006. Lawson,N.D.,and B.M.Weinstein.2002.“In vivo imaging of embryonic vascular development using transgenic zebrafish.”Dev Biol 248(2):307-18. Lefebvre,V.,W.Huang,V.R.Harley,P.N.Goodfellow,and B.de Crombrugghe.1997.“SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II)collagen gene.”Mol Cell Biol 17(4):2336-46. Love,M.I.,W.Huber,and S.Anders.2014.“Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”Genome Biol 15(12):550.doi:10.1186 / s13059-014-0550-8. Matsui,T.,M.Kanai-Azuma,K.Hara,S.Matoba,R.Hiramatsu,H.Kawakami,M.Kurohmaru,P.Koopman,and Y.Kanai.2006.“Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice.”J Cell Sci 119(Pt 17):3513-26.doi:10.1242 / jcs.03081. Mitchell,R.E.,L.F.Huitema,R.E.Skinner,L.H.Brunt,C.Severn,S.Schulte-Merker,and C.L.Hammond.2013.“New tools for studying osteoarthritis genetics in zebrafish.”Osteoarthritis Cartilage 21(2):269-78.doi:10.1016 / j.joca.2012.11.004. Mittal,D.,A.Young,K.Stannard,M.Yong,M.W.Teng,B.Allard,J.Stagg,and M.J.Smyth.2014.“Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.”Cancer Res 74(14):3652-8.doi:10.1158 / 0008-5472.CAN-14-0957. Moellering,R.E.,M.Cornejo,T.N.Davis,C.Del Bianco,J.C.Aster,S.C.Blacklow,A.L.Kung,D.G.Gilliland,G.L.Verdine,and J.E.Bradner.2009.“Direct inhibition of the NOTCH transcription factor complex.”Nature 462(7270):182-8.doi:10.1038 / nature08543. Mohammed,H.,C.D’Santos,A.A.Serandour,H.R.Ali,G.D.Brown,A.Atkins,O.M.Rueda,K.A.Holmes,V.Theodorou,J.L.Robinson,W.Zwart,A.Saadi,C.S.Ross-Innes,S.F.Chin,S.Menon,J.Stingl,C.Palmieri,C.Caldas,and J.S.Carroll.2013.“Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.”Cell Rep 3(2):342-9.doi:10.1016 / j.celrep.2013.01.010. Mureev,S.,O.Kovtun,U.T.Nguyen,and K.Alexandrov.2009.“Species-independent translational leaders facilitate cell-free expression.”Nat Biotechnol 27(8):747-52.doi:10.1038 / nbt.1556. Pendeville,H.,M.Winandy,I.Manfroid,O.Nivelles,P.Motte,V.Pasque,B.Peers,I.Struman,J.A.Martial,and M.L.Voz.2008.“Zebrafish Sox7 and Sox18 function together to control arterial-venous identity.”Dev Biol 317(2):405-16.doi:10.1016 / j.ydbio.2008.01.028. Pula,B.,M.Olbromski,A.Wojnar,A.Gomulkiewicz,W.Witkiewicz,M.Ugorski,P.Dziegiel,and M.Podhorska-Okolow.2013.“Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma.”Cell Oncol(Dordr)36(6):469-83.doi:10.1007 / s13402-013-0151-7. Robinson,A.S.,S.C.Materna,R.M.Barnes,S.De Val,S.M.Xu,and B.L.Black.2014.“An arterial-specific enhancer of theHuman endothelin converting enzyme 1(ECE1)gene is synergistically activated by Sox17,FoxC2,and Etv2.”Dev Biol 395(2):379-89.doi:10.1016 / j.ydbio.2014.08.027. Sacilotto,N.,R.Monteiro,M.Fritzsche,P.W.Becker,L.Sanchez-Del-Campo,K.Liu,P.Pinheiro,I.Ratnayaka,B.Davies,C.R.Goding,R.Patient,G.Bou-Gharios,and S.De Val.2013.“Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development.”Proc Natl Acad Sci U S A 110(29):11893-8.doi:10.1073 / pnas.1300805110. Sarkar,A.,and K.Hochedlinger.2013.“The sox family of transcription factors:versatile regulators of stem and progenitor cell fate.”Cell Stem Cell 12(1):15-30.doi:10.1016 / j.stem.2012.12.007. Schmidt,D.,M.D.Wilson,C.Spyrou,G.D.Brown,J.Hadfield,and D.T.Odom.2009.“ChIP-seq:usingHigh-throughput sequencing to discover protein-DNA interactions.”Methods 48(3):240-8.doi:10.1016 / j.ymeth.2009.03.001. Sierecki,E.,N.Giles,M.Polinkovsky,M.Moustaqil,K.Alexandrov,and Y.Gambin.2013.“A cell-free approach to accelerate the study of protein-protein interactions in vitro.”Interface Focus 3(5):20130018.doi:10.1098 / rsfs.2013.0018. Sierecki,E.,L.M.Stevers,N.Giles,M.E.Polinkovsky,M.Moustaqil,S.Mureev,W.A.Johnston,M.Dahmer-Heath,D.Skalamera,T.J.Gonda,B.Gabrielli,B.M.Collins,K.Alexandrov,and Y.Gambin.2014.“Rapid mapping of interactions betweenHuman SNX-BAR proteins measured in vitro by AlphaScreen and single-molecule spectroscopy.”Mol Cell Proteomics 13(9):2233-45.doi:10.1074 / mcp.M113.037275. Song,H.D.,X.J.Sun,M.Deng,G.W.Zhang,Y.Zhou,X.Y.Wu,Y.Sheng,Y.Chen,Z.Ruan,C.L.Jiang,H.Y.Fan,L.I.Zon,J.P.Kanki,T.X.Liu,A.T.Look,and Z.Chen.2004.“Hematopoietic gene expression profile in zebrafish kidney marrow.”Proc Natl Acad Sci U S A 101(46):16240-5.doi:10.1073 / pnas.0407241101. Thisse,C.,and B.Thisse.2008.“High-resolution in situHybridization to whole-mount zebrafish embryos.”Nat Protoc 3(1):59-69.doi:10.1038 / nprot.2007.514. Wythe,J.D.,L.T.Dang,W.P.Devine,E.Boudreau,S.T.Artap,D.He,W.Schachterle,D.Y.Stainier,P.Oettgen,B.L.Black,B.G.Bruneau,and J.E.Fish.2013.“ETS factors regulate Vegf-dependent arterial specification.”Dev Cell 26(1):45-58.doi:10.1016 / j.devcel.2013.06.007. Yang,H.,S.Lee,S.Lee,K.Kim,Y.Yang,J.H.Kim,R.H.Adams,J.M.Wells,S.J.Morrison,G.Y.Koh,and I.Kim.2013.“Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice.”J Clin Invest 123(1):418-31.doi:10.1172 / JCI64547. Young,N.,C.N.Hahn,A.Poh,C.Dong,D.Wilhelm,J.Olsson,G.E.Muscat,P.Parsons,J.R.Gamble,and P.Koopman.2006.“Effect of disrupted SOX18 transcription factor function on tumor growth,vascularization,and endothelial development.”J Natl Cancer Inst 98(15):1060-7.doi:10.1093 / jnci / djj299. Zhang,X.,P.Yue,B.D.Page,T.Li,W.Zhao,A.T.Namanja,D.Paladino,J.Zhao,Y.Chen,P.T.Gunning,and J.Turkson.2012.“Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regressesHuman breast and lung cancer xenografts.”Proc Natl Acad Sci U S A 109(24):9623-8.doi:10.1073 / pnas.1121606109. Zhang,Y.,S.Huang,W.Dong,L.Li,Y.Feng,L.Pan,Z.Han,X.Wang,G.Ren,D.Su,B.Huang,and J.Lu.2009.“SOX7,down-regulated in colorectal cancer,induces apoptosis and inhibits proliferation of colorectal cancer cells.”Cancer Lett 277(1):29-37.doi:10.1016 / j.canlet.2008.11.014.

Claims

1. An agent for treating angiogenesis- and / or lymphangiogenesis-associated disease or disorder, comprising a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein the angiogenesis- and / or lymphangiogenesis-associated disease or disorder is a SOX18-dependent cancer selected from the group consisting of sarcoma, carcinoma, lymphoma, leukemia and blastoma; The compound of formula (I) (Z)-N,N-diethyl-2-methoxy-6-(2-(naphthalen-2-yl)vinyl)benzamide; (E)-N,N-diethyl-2-methoxy-6-(2-(naphthalen-2-yl)vinyl)benzamide; 2,4-dimethoxy-6-(2-(naphthalen-2-yl)ethyl)benzoic acid; and 2-(3,4,5-trimethoxyphenethyl)naphthalene an agent that is not a compound selected from 【Chemistry 1】 During the ceremony, R 1 is OH and OR 6 wherein R 6 is C 1 ~C 4 is alkyl; R 2 is COOR 7 and C(O)NR 8 R 9 wherein R 7 , R 8 and R 9 are independently H and C 1 ~C 4 alkyl; R 3 is L-A, where L is C 2 Alkylene and C 2 alkenylene, and A is halo, C 1 ~C 4 Alkyl, O.C. 1 ~C 4 Alkyl, NH 2 , NH(C 1 ~C 4 alkyl), and N(C 1 ~C 4 Alkyl) 2 naphthyl optionally substituted with one or more substituents selected from R 4 is H, OR 10 , halo and C 1 ~C 4 alkyl, where R 10 is H and C 1 ~C 4 alkyl; and R 5 is H, OR 11 , halo and C 1 ~C 4 alkyl, where R 11 is H and C 1 ~C 4 is selected from alkyl.

2. The agent according to claim 1, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, lung cancer, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, uterine cancer, colon cancer, colorectal cancer, gastric cancer, head and neck cancer, liver cancer, kidney cancer, skin cancer, pancreatic cancer, pituitary cancer, musculoskeletal cancer, hemangioma, angioma, angiosarcoma, hepatocellular carcinoma and hepatocellular carcinoma.

3. The method of claim 1 or 2, wherein metastasis of the cancer is prevented and / or inhibited.

4. The compound of formula (I) R 1 is OH and OR 6 wherein R 6 is C 1 ~C 4 is alkyl; R 2 is COOR 7 and C(O)NR 8 R 9 wherein R 7 , R 8 and R 9 are independently H and C 1 ~C 4 alkyl; R 3 is L-A, where L is C 2 Alkylene and C 2 alkenylene, and A is halo, C 1 ~C 4 Alkyl, O.C. 1 ~C 4 Alkyl, NH 2 , NH(C 1 ~C 4 alkyl), and N(C 1 ~C 4 Alkyl) 2 naphthyl optionally substituted with one or more substituents selected from R 4 is H; and R 5 is H, The agent according to any one of claims 1 to 3.

5. The compound of formula (I) R 1 is OH; R 2 is COOR 7 where R 7 is H and C 1 ~C 4 alkyl; R 3 is L-A, where L is C 2 Alkylene and C 2 alkenylene, and A is halo, C 1 ~C 4 Alkyl, O.C. 1 ~C 4 Alkyl, NH 2 , NH(C 1 ~C 4 alkyl), and N(C 1 ~C 4 Alkyl) 2 naphthyl optionally substituted with one or more substituents selected from R 4 is H; and R 5 is H, The agent according to any one of claims 1 to 4.

6. The compound of formula (I) R 1 is OH; R 2 is COOH; R 3 is L-A, where L is C 2 Alkylene and C 2 alkenylene, and A is optionally one or more of halo, C 1-4 Alkyl, O.C. 1-4 Alkyl, NH 2 , NH(C 1-4 alkyl), and N(C 1-4 Alkyl) 2 naphthyl substituted with a group selected from; R 4 is H; and R 5 is H, The agent according to any one of claims 1 to 5.

Citation Information

Patent Citations

  • Synthetic derivatives of lunularic acid, medicaments containing said compounds, method for producing the lunularic acid derivatives and the use thereof

    WO2001074753A1